{"title": "Calendario de vacunaci\u00f3n en reci\u00e9n nacidos prematuros", "author": "Diariofarma", "url": "https://diariofarma.com/2019/11/28/vacunacion-en-prematuros", "hostname": "diariofarma.com", "description": "Vacunaci\u00f3n en prematuros Ponencia de Programa y Registro de Vacunaciones Noviembre 2019 Elaboraci\u00f3n y revisi\u00f3n del documento Elaboraci\u00f3n del documento Grupo de trabajo Vacunaci\u00f3n en prematuros: Aurora Limia S\u00e1nchez, Doctora en Medicina y Cirug\u00eda. Especialista en Microbiolog\u00eda y Parasitolog\u00eda Cl\u00ednica. Jefa de \u00c1rea de Programas de Vacunaci\u00f3n. Ministerio de Sanidad, [\u2026]", "sitename": "Diariofarma", "date": "2019-11-28", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Vacunaci\u00f3n en prematuros\nPonencia de Programa y Registro de Vacunaciones\nNoviembre 2019\n[Elaboraci\u00f3n\ny revisi\u00f3n del documento]\nElaboraci\u00f3n del documento\nGrupo de trabajo Vacunaci\u00f3n en prematuros:\n| ||Aurora Limia S\u00e1nchez, Doctora en Medicina y Cirug\u00eda. Especialista en Microbiolog\u00eda y Parasitolog\u00eda Cl\u00ednica. Jefa de \u00c1rea de Programas de Vacunaci\u00f3n. Ministerio de Sanidad, Consumo y Bienestar Social (MSCBS). Jos\u00e9 Antonio Navarro Alonso, Licenciado en Medicina y Cirug\u00eda, Especialista en Pediatr\u00eda. Jefe del Servicio de Prevenci\u00f3n. Responsable del Programa de Vacunaci\u00f3n de la Regi\u00f3n de Murcia. Luis Carlos Urbiztondo Perdices, Doctor en Medicina y Cirug\u00eda, Especialista en Inmunolog\u00eda y en Medicina Preventiva y Salud P\u00fablica. Jefe de Servicio de Medicina Preventiva. Agencia de Salud P\u00fablica de Catalu\u00f1a.|| ||David Moreno P\u00e9rez, Doctor en Medicina y Cirug\u00eda. Especialista en Pediatr\u00eda y sus \u00c1reas Espec\u00edficas. Infectolog\u00eda Pediatr\u00eda e Inmunodeficiencias, UGC de Pediatr\u00eda, Hospital Materno-Infantil de M\u00e1laga. Plan Estrat\u00e9gico de Vacunaciones. Junta de Andaluc\u00eda. Jos\u00e9 Antonio Taboada Rodr\u00edguez, Licenciado en Medicina y Cirug\u00eda, Jefe del Servicio de control de enfermedades transmisibles. Consejer\u00eda de Sanidad de Galicia. Jos\u00e9 Mar\u00eda Arteagoitia Axpe, Licenciado en Medicina y Cirug\u00eda, Especialista en Medicina Preventiva y Salud P\u00fablica. Jefe de Servicio de Vigilancia y Vacunas. Gobierno Vasco. Ant\u00f2nia Galm\u00e9s Truyols, Licenciada en Medicina y Cirug\u00eda. Coordinadora de vacunas. Gobierno de las Islas Baleares.|\nCoordinaci\u00f3n del grupo de trabajo y del documento: Aurora Limia Sanchez. \u00c1rea de Programas de Vacunaci\u00f3n. Subdirecci\u00f3n General de Promoci\u00f3n de la Salud y Vigilancia en Salud P\u00fablica. Direcci\u00f3n General de Salud P\u00fablica, Calidad e Innovaci\u00f3n. MSCBS.\nLos miembros del grupo de trabajo han realizado declaraci\u00f3n de intereses en relaci\u00f3n con los temas tratados en este documento.\nRevisi\u00f3n\n- Ponencia de Programa y Registro de Vacunaciones. Revisado el 31 de octubre de 2019. Aprobado el d\u00eda 8 de noviembre de 2019.\n- Revisado por\nlas siguientes Asociaciones de Profesionales / Sociedades Cient\u00edficas:\n- Comit\u00e9 Asesor de Vacunas de la Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda (CAV-AEP)\n- Sociedad Espa\u00f1ola de Neonatolog\u00eda (SE-Neo)\n- Asociaci\u00f3n Nacional de Enfermer\u00eda y Vacunas (ANENVAC)\n- Comisi\u00f3n de Salud P\u00fablica. Revisado y aprobado el 14 de noviembre de 2019.\nLa informaci\u00f3n contenida en este documento deber\u00e1 referenciarse en caso de utilizaci\u00f3n\nReferencia sugerida:\nGrupo de trabajo vacunaci\u00f3n en prematuros de la Ponencia de Programa y Registro de Vacunaciones. Vacunaci\u00f3n en prematuros. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, Consumo y Bienestar Social, noviembre 2019.\n2\nVacunaci\u00f3n en Prematuros\n[Contenido ] [Elaboraci\u00f3n y\nrevisi\u00f3n del documento.................................................. 2 ](#_Toc50994) [Contenido........................................................................................... 3 ](#_Toc50995) [Acr\u00f3nimos\nutilizados............................................................................ 3 ](#_Toc50996) [Resumen ejecutivo.............................................................................. 4 ](#_Toc50997) [Executive summary -............................................................................ 4 ](#_Toc50998) [1. Introducci\u00f3n................................................................................... 5 ](#_Toc50999) [2. Tosferina........................................................................................ 6 ](#_Toc51000) [3. Hepatitis B...................................................................................... 8 ](#_Toc51001) [4. Enfermedad invasiva por bacterias capsuladas.................................. 9 ](#_Toc51002) [5. Rotavirus...................................................................................... 11 ](#_Toc51003) [6. Gripe............................................................................................ 13 ](#_Toc51004) [7. Seguridad de las vacunas............................................................... 14 ](#_Toc51005) [8. Recomendaciones......................................................................... 15 ](#_Toc51006) [9. Bibliograf\u00eda................................................................................... 16 ](#_Toc51007)\n[Acr\u00f3nimos utilizados]\n|ACIP||Comit\u00e9 Asesor de Vacunaciones de los CDC de EEUU (Advisory Committee on Immunization Practices)|\n|AgHBs||Ant\u00edgeno de superficie del VHB|\n|Anti-HBc||Anticuerpos frente al ant\u00edgeno core del VHB|\n|Anti-HBs||Anticuerpos frente al ant\u00edgeno de superficie del VHB|\n|CCAA||Comunidades aut\u00f3nomas y ciudades de Ceuta y Melilla|\n|CDC||Centros de Prevenci\u00f3n y Control de Enfermedades de EEUU (Centers for Disease Control and Prevention)|\n|CISNS||Consejo Interterritorial del Sistema Nacional de Salud|\n|dTpa||Vacuna frente a difteria, t\u00e9tanos y tosferina acelular con baja carga antig\u00e9nica|\n|ECDC||Centro Europeo para la Prevenci\u00f3n y el Control de Enfermedades (European Centre for Disease Prevention and Control)|\n|EG||Edad gestacional|\n|EEUU||Estados Unidos de Am\u00e9rica|\n|EMA||Agencia Europea de Medicamentos (European Medicines Agency)|\n|EMI||Enfermedad meningoc\u00f3cica invasora o invasiva|\n|ENI||Enfermedad neumoc\u00f3cica invasora o invasiva|\n|FHA||Hemaglutinina filamentosa|\n|FT||Ficha t\u00e9cnica|\n|HA||Hepatitis A|\n|HB||Hepatitis B|\n|Hib||Haemophilus influenzae tipo b|\n|IC95%||Intervalo de confianza 95 %|\n|INE||Instituto Nacional de Estad\u00edstica|\n|MenC||Vacuna meningoc\u00f3cica conjugada frente a serogrupo C|\n|MSCBS||Ministerio de Sanidad, Consumo y Bienestar Social|\n|OMS||Organizaci\u00f3n Mundial de la Salud|\n|OR||Odds ratio|\n|RENAVE||Red Nacional de Vigilancia Epidemiol\u00f3gica|\n|RNP||Reci\u00e9n nacido prematuro|\n|TP||Toxina pertussis|\n|TIV||Vacuna antigripal inactivada trivalente|\n|TV||Vacuna triple v\u00edrica (frente a sarampi\u00f3n, rubeola y parotiditis)|\n|UCI||Unidad de cuidados intensivos|\n|UE||Uni\u00f3n Europea|\n|VNC||Vacuna neumoc\u00f3cica conjugada|\n|VNC13||Vacuna neumoc\u00f3cica conjugada de 13 serotipos|\n|VHB||Virus de la hepatitis B|\n|VPI||Vacuna de poliovirus inactivada|\n3\n[Resumen\nejecutivo ]\nLa poblaci\u00f3n con antecedente personal de prematuridad, es decir, nacida antes de la semana 37 de gestaci\u00f3n, tiene mayor riesgo de sufrir ciertas enfermedades inmunoprevenibles, sobre todo si el nacimiento es anterior a la semana 28, y este riesgo perdura hasta aproximadamente los 24 meses de edad.\nCon el objetivo de realizar recomendaciones espec\u00edficas para este grupo de poblaci\u00f3n, se ha revisado la evidencia de la vacunaci\u00f3n en la prevenci\u00f3n de enfermedades que suponen mayor riesgo, su seguridad, as\u00ed como las recomendaciones realizadas en pa\u00edses de nuestro entorno. En concreto, se ha evaluado la vacunaci\u00f3n frente a tosferina, hepatitis B, enfermedad invasiva por bacterias capsuladas, rotavirus y gripe.\nSe recomienda la vacunaci\u00f3n de los prematuros seg\u00fan la edad cronol\u00f3gica, sin tener en cuenta el peso al nacer ni la edad gestacional. Se utilizar\u00e1 la misma pauta de vacunaci\u00f3n que en nacidos a t\u00e9rmino, siendo de enorme importancia la vacunaci\u00f3n \u201cen tiempo\u201d y comenzando el mismo d\u00eda que se cumplen los dos meses de edad o lo antes posible tras ese momento. Se introduce la vacunaci\u00f3n frente a rotavirus en este grupo de poblaci\u00f3n y la vacunaci\u00f3n anual frente a la gripe en los nacidos antes de la semana 32 de gestaci\u00f3n. Adem\u00e1s, para proteger a los reci\u00e9n nacidos durante los primeros meses de vida, es fundamental la vacunaci\u00f3n de embarazadas frente a la gripe en cualquier trimestre de gestaci\u00f3n y frente a la tosferina a partir de la semana 27 de gestaci\u00f3n (ver detalles en el apartado de recomendaciones).\n[Executive summary ]\n\u201cVaccination of preterm infants\u201d. Technical Advisory Committee on Immunization Programme and Registries.\nPreterm infants, who are those born before the 37th week of gestation, have a higher risk of suffering certain vaccine preventable diseases, especially when born before the 28th gestational week. This risk lasts up to approximately they are 24 months old.\nWith the objective of making specific recommendations for this population, the evidence of prevention of these diseases by vaccination, its safety and the recommendations made in other neighboring countries, have been reviewed. Specifically, immunization against pertussis, hepatitis B, invasive disease by encapsulated bacteria, rotavirus and influenza has been assessed.\nVaccination of preterm infants is recommended according to their chronological age, using the same schedules as recommended for full-term infants, without correcting for prematurity and regardless of birth weight. It is highly important the timely vaccination beginning on the same day as two months of age or as soon as possible after that date. Vaccination against rotavirus is introduced in this population group and annual vaccination against influenza in those born before the 32nd week of gestation. In addition, in order to protect newborns during the first months of life, the immunization of pregnant women against influenza in any trimester of pregnancy and against pertussis from week 27 of gestation is essential (see details in the recommendations section).\n[1.\nIntroducci\u00f3n ]\nSe consideran reci\u00e9n nacidos prematuros (RNP) a los nacidos con menos de 37 semanas de edad gestacional (EG), estim\u00e1ndose en Espa\u00f1a alrededor del 7 % de los reci\u00e9n nacidos, aproximadamente 28 000 al a\u00f1o, con un aumento del 36 % desde 19961. El estr\u00e9s laboral, el retraso de la maternidad, los problemas de salud en la madre y el aumento de partos m\u00faltiples son las causas identificables fundamentales de ese aumento2.\nLa mayor morbimortalidad en los RNP se observa en los nacimientos con EG entre 28 y 32 semanas (muy prematuros) y, sobre todo, con menos de 28 semanas (prematuros extremos), que suponen en conjunto un 1 % de todos los nacimientos (4300 al a\u00f1o aproximadamente3), as\u00ed como los RNP con muy bajo peso (menos de 1500 g). En la actualidad, en nuestro medio, el 95 % de los RNP con >28 semanas de EG sobrevive, mientras que aquellos con prematuridad extrema y peso <1500 gr lo hacen en el 73 %3.\nLa especial vulnerabilidad a las infecciones en los RNP es mayor a menor EG y peso, incluyendo algunas inmunoprevenibles, como tosferina, gripe y enfermedad neumoc\u00f3cica invasiva (ENI)4,5, que incluso parece mantenerse durante los primeros a\u00f1os de vida5. Entre las razones que pueden explicar esta susceptibilidad a las infecciones se incluye la inmadurez de las barreras cut\u00e1neo-mucosas, la inmadurez del sistema inmunitario (con una menor respuesta a ant\u00edgenos polisac\u00e1ridos capsulares), la menor transferencia de anticuerpos maternos (que comienza alrededor de la semana 17 de gestaci\u00f3n, igual\u00e1ndose las concentraciones en la madre y el feto entre las semanas 32 y 366), la menor tasa de lactancia materna y las patolog\u00edas y tratamientos acompa\u00f1antes a la prematuridad (desnutrici\u00f3n, neumopat\u00eda, el tratamiento prolongado con esteroides, la hospitalizaci\u00f3n prolongada, etc.)4,7. Otros factores contribuyentes pueden ser la presencia de hermanos de corta edad entre los convivientes y el bajo nivel socioecon\u00f3mico2,4.\nLa respuesta inmune de los RNP a las vacunas puede ser inferior a la de nacidos a t\u00e9rmino, sobre todo en aquellos con EG menor de 28 semanas o peso inferior a 1500 g, probablemente debido a una respuesta de linfocitos Th1 reducida y un desequilibrio Th1/Th24. Sin embargo, en general, se alcanzan concentraciones protectoras de anticuerpos a todos los ant\u00edgenos vacunales al completar la primovacunaci\u00f3n. Si bien la mayor\u00eda de estudios publicados son con pautas 3+1, los pa\u00edses con esquemas 2+1 no han comunicado diferencias en la efectividad vacunal seg\u00fan la EG. La respuesta inmune en los RNP es similar a la obtenida en los nacidos a t\u00e9rmino para las vacunas DTP, DTPa, poliovirus 1 y 2, neumococo y meningococo, pero inferior para hepatitis B, Hib y poliovirus 34. Por el momento, su impacto cl\u00ednico real se desconoce, sobre todo en RNP de EG <32 semanas y, a\u00fan m\u00e1s, en los <28 semanas o <1500 g. La informaci\u00f3n sobre la protecci\u00f3n a largo plazo otorgada por estas vacunas es escasa, aunque los datos disponibles sugieren que a partir del segundo a\u00f1o de vida adquieren memoria inmunol\u00f3gica adecuada y que lograr\u00edan una protecci\u00f3n adecuada, similar a la observada en los nacidos a t\u00e9rmino8,9,10.\nTodas estas razones expuestas previamente determinan la prioridad de vacunar a esta poblaci\u00f3n de manera \u00f3ptima. En ausencia de contraindicaciones, se recomienda iniciar la vacunaci\u00f3n de RNP a la edad cronol\u00f3gica correspondiente, es decir, a los 2 meses, independientemente de la EG o el peso11,12. Sin embargo, es frecuente que se produzcan retrasos en la vacunaci\u00f3n de los RNP, sobre todo en los primeros 6 meses de vida, por diferentes razones, como la frecuencia de patolog\u00eda intercurrente que contraindica temporalmente la vacunaci\u00f3n y el temor o desconocimiento sobre la seguridad y reactogenicidad de las vacunas en esta poblaci\u00f3n13,14.\nEn el documento de la Ponencia de Programas y Registro de Vacunaciones de 2016, \u201cRevisi\u00f3n del calendario de vacunaci\u00f3n\u201d12 se recomienda la vacunaci\u00f3n de los reci\u00e9n nacidos con prematuridad seg\u00fan la edad cronol\u00f3gica, con el mismo esquema que en los nacidos a t\u00e9rmino.\nTeniendo en cuenta la preocupaci\u00f3n que suscita la vacunaci\u00f3n en el manejo de prematuros por parte del personal sanitario, se revisa en este documento la evidencia sobre estrategias y esquemas de vacunaci\u00f3n, con especial atenci\u00f3n a la prevenci\u00f3n de tosferina, hepatitis B, enfermedad invasiva por Haemophilus influenzae tipo b, meningococo y neumococo, rotavirus y gripe, por la mayor morbimortalidad de estas enfermedades y por la peor respuesta inmune a algunas de las vacunas. Adem\u00e1s, se presenta un apartado sobre la seguridad de las vacunas en este grupo de poblaci\u00f3n.\nEn este documento no se abordan otras medidas de inmunoprevenci\u00f3n, como la utilizaci\u00f3n de anticuerpos monoclonales.\n[2.\nTosferina ]\nLos lactantes nacidos prematuramente tienen un mayor riesgo de padecer tosferina y de que la enfermedad sea m\u00e1s grave debido a su inmadurez inmunitaria y a la transferencia incompleta de\nanticuerpos maternos15,16,17,18.\nLa estrategia actual de prevenci\u00f3n de la tosferina en reci\u00e9n nacidos, tanto en prematuros como a t\u00e9rmino, en ausencia de una protecci\u00f3n comunitaria adecuada19, se fundamenta en dos pilares b\u00e1sicos: la inmunizaci\u00f3n activa del lactante y, por otro, en la inmunizaci\u00f3n pasiva mediante la vacunaci\u00f3n de la embarazada.\nInmunizaci\u00f3n activa. Aunque no se ha establecido un patr\u00f3n serol\u00f3gico subrogado de protecci\u00f3n, se dispone de varias experiencias que han analizado la respuesta inmune en lactantes prematuros. En menores de 32 semanas (EG media de 28,5 semanas) la respuesta inmune IgG a los componentes de una vacuna combinada que inclu\u00eda cinco ant\u00edgenos de tosferina fue similar a la alcanzada en nacidos a t\u00e9rmino, tras una pauta acelerada de vacunaci\u00f3n a los 2, 3 y 4 meses20. Investigadores espa\u00f1oles encontraron hallazgos similares tras la recepci\u00f3n de la tercera dosis de una vacuna hexavalente de tres componentes de tosferina administrada en pauta 2, 4 y 6 meses, al comparar las respuestas en prematuros con EG comprendida entre las semanas 24 y 36 con las observadas en nacidos a t\u00e9rmino. Las tasas de seropositividad tras la vacunaci\u00f3n fueron al menos del 98,9 % tanto en prematuros como en nacidos a t\u00e9rmino21. Una vacuna combinada, DTPa-HB con tres componentes de tosferina administrada con un esquema de vacunaci\u00f3n de 3, 5 y 11 meses en 34 prematuros con EG media de 32 semanas, produjo seroconversi\u00f3n a los tres componentes de la tosferina en todos ellos menos en uno tras las series primarias y en todos ellos tras la dosis de recuerdo. Tras las series primarias se constat\u00f3 una menor media geom\u00e9trica de los t\u00edtulos de anticuerpos en los prematuros respecto de los nacidos a t\u00e9rmino, que desapareci\u00f3, excepto para la pertactina, tras la dosis de recuerdo22. Tras la administraci\u00f3n de una vacuna acelular de dos componentes de tosferina en pauta de 2, 3 y 4 meses a prematuros con EG media de 30,8 semanas, la media geom\u00e9trica de anticuerpos frente a toxina pertussis (TP) y a hemaglutinina filamentosa (FHA) fue significativamente inferior en los prematuros, aunque en m\u00e1s del 82,6 % y del 93,5 % se multiplicaron por cuatro las concentraciones de anticuerpos, respecto a las basales, frente a FHA y TP, respectivamente23.\nEn cuanto a la inmunidad celular generada tras la vacunaci\u00f3n en prematuros, un estudio realizado en B\u00e9lgica con lactantes nacidos con menos de 31 semanas comprob\u00f3 c\u00f3mo persist\u00eda la inmunidad celular al a\u00f1o de edad en los primovacunados con vacuna hexavalente a los 2, 3 y 4 meses24.\nEs importante tener presente que, aunque para determinados ant\u00edgenos la respuesta inmune al componente de tosferina pudiera ser inferior en prematuros, la vacuna es capaz de generar memoria inmunol\u00f3gica, puesta de manifiesto tras la administraci\u00f3n de una dosis de recuerdo25,26.\nEn relaci\u00f3n a la efectividad de la vacuna acelular frente a la tosferina, un estudio realizado en Dinamarca16 compar\u00f3, tras un seguimiento de hasta los dos a\u00f1os de edad, la efectividad de una vacuna acelular monocomponente en lactantes de 20 a 36 semanas de gestaci\u00f3n frente a los de 37 a 41 semanas en r\u00e9gimen 3, 5 y 12 meses. En los prematuros, la efectividad de la vacuna para una, dos y tres dosis fue del 45 %, 77 % y 90 %, respectivamente, y del 50 %, 85 % y 96 % en los nacidos a t\u00e9rmino, respectivamente (p=0,3643). Se observaron hallazgos similares en un estudio de cohortes en Noruega18, donde tras una pauta a los 3, 5 y 11-12 meses en prematuros (23 a 36 semanas) y en nacidos a t\u00e9rmino (\u226537 semanas), la efectividad de la vacuna tras una o dos dosis para tosferina confirmada fue similar entre ambos grupos: 73,0 % y 80,1 % frente a 52,5 % y 81,9 %, respectivamente. Para las hospitalizaciones fue del 71,2 % y 93,8 % frente a 60,7 % y 90,6 %, respectivamente.\nLa mayor\u00eda de las autoridades sanitarias del mundo no abogan por un calendario espec\u00edfico de vacunaci\u00f3n frente a la tosferina para prematuros, excepto las de Suiza27 y solo para los de EG menor de 33 semanas, para los que recomiendan un esquema de tres dosis en primovacunaci\u00f3n, en lugar de las dos dosis para ni\u00f1os no prematuros. Todas ellas coinciden en la vacunaci\u00f3n en tiempo, esto es, a las 8 y 16 semanas de edad. Con el objetivo de alcanzar una protecci\u00f3n precoz se recomienda, en algunos pa\u00edses, adelantar a las seis semanas la edad para recibir la primera dosis de vacuna18,28.\nInmunizaci\u00f3n pasiva. El segundo pilar en la protecci\u00f3n de prematuros frente a la tosferina reside en la vacunaci\u00f3n de embarazadas con dTpa, de manera similar a la protecci\u00f3n obtenida frente a la gripe o frente al t\u00e9tanos neonatal. Esta estrategia se fundamenta en la existencia de transferencia de anticuerpos IgG a trav\u00e9s de la placenta, alcanzando una alta correlaci\u00f3n entre los niveles de anticuerpos de la gestante y los del reci\u00e9n nacido29. Este paso de anticuerpos al feto comienza en el segundo trimestre de gestaci\u00f3n, alrededor de la semana 1730,31, con un pico de transferencia a partir de la semana 3232, igualando las concentraciones maternas entre las semanas 32 a 36, para sobrepasarlas en la semana 376. Por otra parte, la vida media de los anticuerpos en el lactante es corta, no durando m\u00e1s all\u00e1 de los 2 a 3 meses de vida33.\nUn estudio prospectivo realizado en Israel encontr\u00f3 un mayor t\u00edtulo de anticuerpos y de mayor avidez frente a TP y FHA en cord\u00f3n umbilical cuando las gestantes recibieron la vacuna entre las semanas 27 y 30, inclusive, que cuando se vacunaban con 32 o m\u00e1s semanas34,35. En una l\u00ednea similar, un estudio observacional y prospectivo en los Estados Unidos36 que compar\u00f3 la vacunaci\u00f3n en el tercer trimestre con la no vacunaci\u00f3n, encontr\u00f3 que las concentraciones geom\u00e9tricas medias de anticuerpos anti-PT eran mayores cuando la vacuna dTpa se administr\u00f3 entre las semanas 27 y 30. Resultados ligeramente diferentes encontr\u00f3 otro estudio observacional y prospectivo llevado a cabo en gestantes en Suiza37 que compar\u00f3 las concentraciones de anticuerpos en cord\u00f3n seg\u00fan la EG (entre la semana 13 y la 41) en la que recibieron la vacuna dTpa. La concentraci\u00f3n geom\u00e9trica media de anticuerpos anti-PT y anti-FHA en el cord\u00f3n umbilical alcanzaban su m\u00e1ximo cuando la vacunaci\u00f3n ten\u00eda lugar entre las semanas 22 y 33.\nOtro estudio observacional prospectivo estudi\u00f3 la cin\u00e9tica de anticuerpos frente a TP y FHA en prematuros de los que un 80 % y un 20 % ten\u00edan una EG entre 34 y 36 y entre 30 y 33 semanas, respectivamente38. Se analiz\u00f3 la sangre de cord\u00f3n de prematuros cuyas madres fueron vacunadas entre las semanas 13 a 25 o a partir de la semana 26. Tras la vacunaci\u00f3n gestacional precoz, la relativamente baja transferencia de anticuerpos maternos se compens\u00f3 con la mayor duraci\u00f3n del tiempo total de la misma, lo que condujo a una gran concentraci\u00f3n de anticuerpos en el feto. La aplicaci\u00f3n pr\u00e1ctica del estudio reside en que los nacidos con prematuridad entre las semanas 30 y 36 se beneficiar\u00edan de la vacunaci\u00f3n de la gestante en el segundo trimestre de embarazo.\nEstos estudios de la cin\u00e9tica de anticuerpos han condicionado el momento que los pa\u00edses han seleccionado para vacunar a las embarazadas. As\u00ed, en el Reino Unido, al inicio del programa de vacunaci\u00f3n de embarazadas en 2012, se aconsejaba la administraci\u00f3n entre las semanas 28 y 32 para pasar a recomendar, desde abril de 2016, la vacunaci\u00f3n a partir de la semana 1639. Desde entonces, la vacunaci\u00f3n parece haber impactado positivamente en la incidencia de la enfermedad en los prematuros40. En los Estados Unidos se aconseja vacunar entre las semanas 27 y 36, pero preferencialmente m\u00e1s pr\u00f3ximo a la semana 2741 y en Australia la recomendaci\u00f3n incluye desde la semana 20 a la 3228 para intentar conseguir la protecci\u00f3n frente a la tosferina tambi\u00e9n en prematuros42. En Espa\u00f1a se aconseja la administraci\u00f3n de la vacuna dTpa entre las semanas de gestaci\u00f3n 27-28 y 36 e, idealmente, entre las semanas 28 y 3243.\nEn prematuros con EG <32 semanas que no se beneficien de la transferencia pasiva de anticuerpos, la IgA secretora frente a TP y frente a FHA, presente en la leche materna hasta las ocho semanas, puede proporcionarles cierta protecci\u00f3n34,44. Como medida adicional de protecci\u00f3n para los nacidos en prematuridad, se recomienda la vacunaci\u00f3n del personal sanitario implicado en sus cuidados45.\nRecomendaciones\n- A la vista de lo expuesto anteriormente no parece necesario modificar, para los prematuros, la actual pauta de vacunaci\u00f3n 2+1, aunque es de capital importancia que se comience, en ausencia de contraindicaciones, en el momento de cumplir los dos meses de vida o lo antes posible tras ese momento.\n- La estrategia para evitar o mitigar la tosferina en los 2-3 primeros meses de vida del lactante prematuro incluye la vacunaci\u00f3n de embarazadas con dTpa a partir de la semanas 27, pero preferentemente en la semana 27 o 28, incrementando en lo posible las coberturas actuales.\nEn embarazadas con alto riesgo de parto prematuro y cl\u00ednicamente estables se puede valorar la vacunaci\u00f3n a partir de la semana 20 de gestaci\u00f3n.\n[3.\nHepatitis B ]\nLa incidencia de hepatitis B en edad pedi\u00e1trica en Espa\u00f1a es muy baja, debido al patr\u00f3n epidemiol\u00f3gico de la infecci\u00f3n en nuestro pa\u00eds y a la inclusi\u00f3n de la vacunaci\u00f3n en el calendario desde los a\u00f1os 90. Persiste un cierto riesgo de infecci\u00f3n perinatal, fundamentalmente por transmisi\u00f3n durante el parto en la descendencia de madres portadoras. Debido a la tolerancia inmunol\u00f3gica frente al virus de la hepatitis B (VHB), la infecci\u00f3n en reci\u00e9n nacidos es asintom\u00e1tica en la pr\u00e1ctica totalidad de los casos, pero el riesgo de persistencia de la infecci\u00f3n es muy elevado, as\u00ed como las complicaciones que pueden aparecer en los portadores cr\u00f3nicos como cirrosis o hepatocarcinoma. Por estos motivos, se recomienda el cribado de las gestantes y, en caso de infecci\u00f3n, la profilaxis posexposici\u00f3n del reci\u00e9n nacido46.\nLa respuesta a la vacuna de la hepatitis B administrada antes del primer mes de edad es inferior en los prematuros que en los nacidos a t\u00e9rmino. Desde los a\u00f1os noventa hay evidencia de que las tasas de seroconversi\u00f3n y los t\u00edtulos de anticuerpos son proporcionales a la madurez del reci\u00e9n nacido47,48. Aunque no hay un umbral concreto de EG o de peso al nacer que se correlacione con una respuesta de anticuerpos anti-HBs insuficiente tras la vacunaci\u00f3n, cl\u00e1sicamente se ha utilizado este \u00faltimo para determinar la pauta de vacunaci\u00f3n y se ha considerado como umbral para administrar una dosis adicional de vacuna un peso al nacer inferior a 2000 g. A partir del primer mes de vida los prematuros cl\u00ednicamente estables tienen una respuesta a la vacunaci\u00f3n que es comparable a la de los reci\u00e9n nacidos a t\u00e9rmino independientemente del peso inicial al nacer o la EG49,50. La administraci\u00f3n de vacuna hexavalente a los 2, 4 y 11 meses de edad, seg\u00fan la pauta indicada en el calendario com\u00fan de vacunaci\u00f3n, proporciona una protecci\u00f3n adecuada contra la hepatitis B en los nacidos con prematuridad.\nEn la actualidad, en Espa\u00f1a se recomienda la vacunaci\u00f3n inmediatamente posterior al nacimiento para el control de la infecci\u00f3n perinatal por VHB en caso de que la gestante sea portadora de VHB, es decir que presente AgHBs(+), dada la alta capacidad infectiva del VHB en el entorno del embarazo-parto12. La inmunoprofilaxis de la transmisi\u00f3n vertical desde una madre portadora, o desde madres sin control serol\u00f3gico del AgHBs, debe realizarse mediante la administraci\u00f3n de vacuna de hepatitis B monocomponente e inmunoglobulina hiperinmune anti-hepatitis B (0,5 ml) administradas en lugares separados durante las primeras 12 horas de vida51. Se recomienda completar la pauta con vacuna hexavalente en las edades propuestas en el calendario de vacunaci\u00f3n (2, 4 y 11 meses). Esta recomendaci\u00f3n es v\u00e1lida tanto para los reci\u00e9n nacidos a t\u00e9rmino como para los nacidos con prematuridad y cumple los requisitos de las pautas utilizadas en los reci\u00e9n nacidos con un peso inferior a 2000 g: I) reciben un total de 4 dosis (en estos RN la dosis de nacimiento no se contabiliza como parte de la serie primaria est\u00e1ndar de 3 dosis que deben administrarse de acuerdo con el calendario de vacunaci\u00f3n52); II) la segunda dosis se administra a los dos meses de edad, con lo que cumple el intervalo m\u00ednimo de 4 semanas con similar inmunogenicidad; y III) la vacunaci\u00f3n finaliza despu\u00e9s de los 6 meses de edad. La \u00faltima dosis, administrada a los 11 meses, act\u00faa como refuerzo y producir\u00e1 una respuesta superior que la de las pautas finalizadas a los 6 meses, ya que un mayor intervalo respecto a la dosis previa produce mayor concentraci\u00f3n final de anticuerpos anti-HBs49.\nRecomendaciones\n- Las recomendaciones de vacunaci\u00f3n contra la hepatitis B actuales son v\u00e1lidas tanto para los nacidos a t\u00e9rmino como para los prematuros, que deben ser vacunados de acuerdo con el calendario de vacunaci\u00f3n com\u00fan vigente, es decir, a los 2, 4 y 11 meses de edad cronol\u00f3gica.\n- En el caso de iniciarse la vacunaci\u00f3n al nacimiento para evitar la infecci\u00f3n perinatal por el virus de la hepatitis B en hijos o hijas de madre portadora o madre sin cribado prenatal, tras la recepci\u00f3n de la primera dosis de vacuna monocomponente de hepatitis B y de la inmunoglobulina hiperinmune anti-hepatitis B, que deben administrarse en las primeras 12 horas de vida, se continuar\u00e1 la vacunaci\u00f3n con vacuna hexavalente, como en el resto de la poblaci\u00f3n infantil, sin que sea preciso tener en cuenta el peso al nacimiento53.\n[4.\nEnfermedad invasiva por bacterias capsuladas ]\nLa enfermedad invasiva por Haemophilus influenzae tipo b (Hib), Streptococcus pneumoniae o neumococo y Neisseria meningitidis o meningococo es m\u00e1s frecuente y causa mayor mortalidad en prematuros que en nacidos a t\u00e9rmino54,55.\nEn general, hay pocos estudios sobre la efectividad de las vacunas frente a Hib, meningococo de serogrupo C y neumococo en prematuros, sobre todo con esquemas 2+1 en el caso de las dos primeras. Al igual que ocurre con otras vacunas, la respuesta inmune a las vacunas disponibles frente a enfermedades causadas por estos microorganismos es peor en prematuros que en nacidos a t\u00e9rmino y est\u00e1 influenciada por la EG y el peso al nacer4,56.\nLos prematuros tienen un riesgo incrementado de presentar enfermedad neumoc\u00f3cica invasiva (ENI) durante los dos primeros a\u00f1os de vida. En un estudio en Noruega se observ\u00f3 que la vacunaci\u00f3n con la pauta recomendada en el momento del estudio, a los 3 y 5 meses, ten\u00eda impacto en la prevenci\u00f3n de la enfermedad desde los 6 meses de edad, por lo que se recomendaba iniciar la vacunaci\u00f3n antes de los 3 meses5. En Inglaterra, se realiz\u00f3 un an\u00e1lisis de los datos de vigilancia entre enero de 2013 y diciembre de 2016, detectando 517 casos de ENI en menores de un a\u00f1o de edad. Se observ\u00f3 mayor tasa de incidencia de ENI (49 frente a 17 por 100 000) y un mayor riesgo, estad\u00edsticamente significativo, de desarrollar esta enfermedad (raz\u00f3n de tasa de incidencia 2,87; IC95%: 2,28-3,59; p <0,001) en prematuros con respecto a los nacidos a t\u00e9rmino, tanto por serotipos incluidos en las VNC como en los no incluidos. Tanto la incidencia como el riesgo de ENI fueron superiores en los prematuros con EG <28 semanas (150 por 100 000 y raz\u00f3n de tasas de 8,8; p <0,001). Mientras que en los prematuros con EG entre 32 y 37 semanas la ENI ocurr\u00eda con mayor frecuencia tras los 3 meses de edad, en aquellos con EG <32 semanas el riesgo de ENI era mayor en el primer mes de vida, particularmente en los dos primeros d\u00edas de vida, lo que sugiere transmisi\u00f3n vertical durante el parto. Los serotipos vacunales causantes de ENI m\u00e1s frecuentes fueron el serotipo 3, seguido del 19A, que era lo esperable dada la menor respuesta a estos serotipos, y la mayor\u00eda de los casos eran ni\u00f1os no vacunados o con vacunaci\u00f3n incompleta, ya fuera por edad o por retraso en la vacunaci\u00f3n; enfatizando la necesidad de vacunar a tiempo. Puesto que no se observaron diferencias entre los serotipos causantes de ENI en funci\u00f3n de la prematuridad o el nacimiento a t\u00e9rmino, los autores consideraron que los defectos en la respuesta inmune causados por la prematuridad ocasionan un mayor progreso desde la colonizaci\u00f3n a la enfermedad y que parece poco probable que un aumento de dosis en primovacunaci\u00f3n tenga impacto en la ENI en prematuros57,58.\nTras tres dosis de primovacunaci\u00f3n con VNC7 en 60 prematuros, se alcanzaron t\u00edtulos protectores de anticuerpos en el 91-100 %, con datos similares tras la dosis de recuerdo. Comparado con los nacidos a t\u00e9rmino, la prematuridad afectaba negativamente la respuesta inmune frente a los serotipos 4, 6B, 14, 19F y 23F59. En un ensayo cl\u00ednico realizado en el Reino Unido para explorar un esquema reducido (a los 2 y\n4 meses de edad), acelerado (2, 3 y 4 meses) o extendido (2, 4 y 6 meses) de primovacunaci\u00f3n con VNC13\nen 199 prematuros, se observ\u00f3 que el 75 % (IC95%: 62-85), 88 % (IC95%: 76-95) y 97 % (IC95%: 87-99) de los participantes de cada grupo, respectivamente, presentaban concentraciones de anticuerpos protectores para al menos la mitad de los serotipos contenidos en la vacuna. Tras la dosis de recuerdo se observaron concentraciones de anticuerpos menores en los prematuros que recibieron esquema extendido con respecto a los que recibieron los esquemas reducido (en 9 de los 13 serotipos) y acelerado (en 4 de los 13 serotipos) y la diferencia era estad\u00edsticamente significativa. Sin embargo, casi todos los participantes presentaban concentraciones de anticuerpos protectores independientemente del esquema utilizado. Por lo tanto, el esquema reducido tambi\u00e9n parece ser el m\u00e1s adecuado para prematuros60. Con respecto a la persistencia de la protecci\u00f3n generada tras la vacunaci\u00f3n, un estudio la evalu\u00f3 a 1 y 2 a\u00f1os en 100 prematuros y en 100 nacidos a t\u00e9rmino vacunados con VNC13 a los 2, 3, 4 y 12 meses de edad. Las concentraciones de anticuerpos descendieron con respecto a los observados un mes tras la vacunaci\u00f3n, pero eran superiores a los t\u00edtulos observados antes de la vacunaci\u00f3n. Se observaron t\u00edtulos de anticuerpos menores frente a la mayor\u00eda de los serotipos en los prematuros con respecto a los nacidos a t\u00e9rmino, con diferencia estad\u00edsticamente significativa para los serotipos 6B, 18C, 19A, 19F y 23F (los serotipos 5, 6A y 9V se mostraron significativamente m\u00e1s bajos en prematuros solamente tras el primer a\u00f1o de seguimiento)61.\nCon respecto a la vacunaci\u00f3n frente a Hib, tras una pauta de primovacunaci\u00f3n a los 2 y 4 meses, se observ\u00f3 una respuesta de anticuerpos protectores significativamente inferior respecto de los nacidos a t\u00e9rmino, pero esta diferencia desaparec\u00eda tras la administraci\u00f3n de la dosis de recuerdo a los 12 meses12,62. En un estudio realizado en Jap\u00f3n (esquema 3+1), se observaron tambi\u00e9n menores t\u00edtulos de anticuerpos en prematuros que en los nacidos a t\u00e9rmino tras la administraci\u00f3n de las 3 dosis de primovacunaci\u00f3n (85,2 frente a 92,4 %, respectivamente), aunque la diferencia no era estad\u00edsticamente significativa. Los t\u00edtulos de anticuerpos fueron menores a menor edad de comienzo de la vacunaci\u00f3n4,63. En otro estudio realizado con vacuna hexavalente, tambi\u00e9n con esquema 3+1, se observ\u00f3 que, a pesar de t\u00edtulos menores de anticuerpos tras la primovacunaci\u00f3n, el 98,2 % de los prematuros vacunados alcanzaban t\u00edtulos protectores tras la dosis de recuerdo, lo que sugiere el desarrollo de memoria inmune tras la primovacunaci\u00f3n64. En Espa\u00f1a desde la introducci\u00f3n de la vacuna en calendario infantil en 1997, la incidencia de la enfermedad invasiva por H. influenzae es muy baja, present\u00e1ndose la mayor\u00eda de los casos en poblaci\u00f3n mayor y por cepas no tipificables65.\nHay pocos ensayos realizados con vacuna conjugada frente a meningococo de serogrupo C (MenC) con prematuros. Con un esquema 3+1 (2, 4, 6 y 16-18 meses de edad) no se observaron diferencias en las tasas de seroprotecci\u00f3n en prematuros y en nacidos a t\u00e9rmino tras la primovacunaci\u00f3n, ni tras la administraci\u00f3n de una dosis de recuerdo en el segundo a\u00f1o de vida66,67. Pocos pa\u00edses de nuestro entorno vacunan sistem\u00e1ticamente a la poblaci\u00f3n infantil antes de los 12 meses de edad (Francia, Irlanda, Polonia e Islandia)68 y ninguno de ellos realiza recomendaciones diferenciadas para la poblaci\u00f3n nacida con prematuridad. La administraci\u00f3n sistem\u00e1tica de vacunas conjugadas proporciona una protecci\u00f3n comunitaria que dificulta la circulaci\u00f3n de meningococo de serogrupo C68.\nEn relaci\u00f3n a la seguridad de estas vacunas en prematuros no se han observado diferencias con respecto a nacidos a t\u00e9rmino4,69 (ver apartado 7 sobre seguridad de las vacunas).\nHay diversidad en las recomendaciones de vacunaci\u00f3n frente a neumococo en la infancia en los pa\u00edses de nuestro entorno, aunque en la mayor\u00eda de los pa\u00edses recomiendan una pauta 2+112,70. Algunos de estos pa\u00edses recomiendan reforzar la vacunaci\u00f3n en prematuros con una dosis adicional en la primovacunaci\u00f3n (pauta 3+1), como Francia71, Suiza27, Alemania70 y Australia72 o solo en prematuros con enfermedad pulmonar cr\u00f3nica u otras condiciones que suponen un riesgo alto de ENI como Canad\u00e1 (en las regiones con pauta 2+1)73. Otros, como el Reino Unido74, Irlanda75, Dinamarca76, Finlandia77, Noruega78 o Nueva Zelanda79, mantienen la misma pauta que para poblaci\u00f3n general, independientemente de la EG al nacer, es decir, una pauta 2+1, insistiendo en la vacunaci\u00f3n \u201cen tiempo\u201d.\nLa raz\u00f3n fundamental para no reforzar la vacunaci\u00f3n frente a neumococo y Hib con una dosis adicional en prematuros es la protecci\u00f3n comunitaria que se desarrolla con la vacunaci\u00f3n sistem\u00e1tica infantil cuando se alcanzan altas coberturas80,81. En este sentido, las altas coberturas de vacunaci\u00f3n alcanzadas en la vacunaci\u00f3n sistem\u00e1tica en Espa\u00f1a aseguran la menor circulaci\u00f3n de las cepas cubiertas por las vacunas conjugadas82.\nRecomendaciones\n- Se recomienda la vacunaci\u00f3n frente a H. influenzae tipo b (incluida en la hexavalente), meningococo y neumococo a los prematuros seg\u00fan la edad cronol\u00f3gica recomendada y con la misma pauta que en los nacidos a t\u00e9rmino e independientemente de la edad gestacional, es decir, a los 2, 4 y 11 meses para Hib y neumococo y 4 y 12 meses para meningococo de serogrupo C. Se insiste en la vacunaci\u00f3n \u201cen tiempo\u201d. La protecci\u00f3n comunitaria derivada de las altas coberturas de vacunaci\u00f3n en la infancia apoya esta recomendaci\u00f3n.\n[5.\nRotavirus ]\nEl rotavirus es la causa principal de diarrea en los primeros a\u00f1os de vida y los prematuros son especialmente vulnerables a esta infecci\u00f3n, con cuadros potencialmente m\u00e1s graves que los lactantes a t\u00e9rmino. Este riesgo es inversamente proporcional al peso al nacer83. En un estudio se observ\u00f3 que los lactantes nacidos con peso <2500 g presentaban un riesgo tres veces mayor de hospitalizaci\u00f3n durante una gastroenteritis por rotavirus, incluso meses despu\u00e9s de haber nacido, comparado con los reci\u00e9n nacidos de peso >2 500 g (OR 2,8; IC95%: 1,6-5,0)84. Entre las complicaciones, la deshidrataci\u00f3n grave, las deposiciones sanguinolentas, la distensi\u00f3n abdominal y la enterocolitis necrotizante, son m\u00e1s comunes en los prematuros.\nDebe tenerse presente que tanto en las unidades de neonatolog\u00eda como en otras \u00e1reas de hospitalizaci\u00f3n pedi\u00e1trica se producen brotes de infecci\u00f3n nosocomial por rotavirus85, pudiendo representar una cuarta parte de los brotes epid\u00e9micos por infecciones v\u00edricas en unidades neonatales86.\nActualmente existen dos preparados de vacuna de rotavirus disponibles en Espa\u00f1a, ambas de virus vivos atenuados para administraci\u00f3n por v\u00eda oral: la vacuna pentavalente reasortante humana-bovina (RotaTeq\u00ae, de MSD, con pauta de 3 dosis, para lactantes con antecedente de EG >25 semanas)87 y la vacuna monovalente de origen humano (Rotarix\u00ae, de GlaxoSmithKline, con pauta de 2 dosis, para lactantes con antecedente de EG 27 semanas)88. Seg\u00fan las indicaciones en las fichas t\u00e9cnicas, la primera dosis con la vacuna pentavalente87 se debe administrar entre las semanas 6 y 12 de vida y la pauta debe completarse antes de la semana 32. En el caso de la monovalente88, la primera dosis debe administrarse tambi\u00e9n entre las semanas 6 y 12, aunque se admite la posibilidad de extenderse hasta la semana 20 de vida, y la pauta debe completarse antes de la semana 24. Adem\u00e1s, el retraso en la vacunaci\u00f3n, sobre todo de la primera dosis, se asocia a un mayor riesgo de invaginaci\u00f3n intestinal89. Para ambos preparados, se recomienda un intervalo de al menos 4 semanas entre dosis. Las dos vacunas se pueden administrar concomitantemente con las de calendario infantil si no existe contraindicaci\u00f3n al respecto87,88.\nAmbos preparados demostraron, en ensayos cl\u00ednicos con prematuros, inmunogenicidad, eficacia cl\u00ednica y seguridad similares a las observadas en lactantes a t\u00e9rmino87,88,89,90. En un estudio poscomercializaci\u00f3n realizado en Estados Unidos se observ\u00f3 que la vacunaci\u00f3n sistem\u00e1tica frente a rotavirus en ni\u00f1os <5 a\u00f1os reduc\u00eda la hospitalizaci\u00f3n por rotavirus un 98 % (IC 95%: 93-100 %) en aquellos con antecedente de bajo peso al nacer (<2500 g) y un 93 % (IC95%: 70-98 %) en los de muy bajo peso al nacer (<1 500 g), datos similares a los que tuvieron un peso normal (91 %, IC95%: 90-92 %)91.\nDebido a que son vacunas vivas atenuadas administradas por v\u00eda oral, el virus vacunal puede excretarse por v\u00eda fecal con posible riesgo de diseminaci\u00f3n a otros lactantes o personas de su entorno. La cuantificaci\u00f3n de este fen\u00f3meno var\u00eda seg\u00fan la t\u00e9cnica empleada. Cuando se estudia mediante cultivo de las heces, se detecta virus vacunal en menos del 20 % de los vacunados durante los primeros 7-10 d\u00edas despu\u00e9s de la administraci\u00f3n de la primera dosis92: 17 % con la monovalente y 8,9 % con la pentavalente.\nCon las dosis siguientes, la excreci\u00f3n fecal de virus es m\u00ednima o nula92. La transmisi\u00f3n horizontal del virus vacunal, aun siendo posible87,88,89, no ha sido documentada tras la vacunaci\u00f3n en unidades\nneonatales89,90,91,92,93.\nLa vacunaci\u00f3n frente a rotavirus est\u00e1 incluida en el calendario infantil de algunos pa\u00edses europeos, incluyendo a los prematuros ingresados a partir de las 6 semanas de vida, como Reino Unido, Alemania o Finlandia, aunque el pa\u00eds con la experiencia m\u00e1s prolongada es Australia. En ninguno de estos pa\u00edses se han constatado brotes por virus vacunal en las unidades neonatales. En otros pa\u00edses, como EEUU o Canad\u00e1, no se vacuna de forma generalizada en las unidades neonatales, aunque se realiza en algunos hospitales89. En el estado espa\u00f1ol, la vacunaci\u00f3n frente a rotavirus no est\u00e1 incluida en el calendario de vacunaci\u00f3n infantil aprobado por el Consejo Interterritorial, aunque se recomienda en prematuros <32 semanas en el Pa\u00eds Vasco. Durante 2019, la Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda y la Sociedad Espa\u00f1ola de Neonatolog\u00eda recomiendan la vacunaci\u00f3n en prematuros, aunque est\u00e9n ingresados en la unidad de neonatos94 y algunos hospitales tienen protocolos para ello.\nRespecto a la vacunaci\u00f3n frente a rotavirus en lactantes cuyas madres recibieron anticuerpos monoclonales y f\u00e1rmacos como etanercept con efecto inmunosupresor durante el embarazo, particularmente en la segunda mitad de la gestaci\u00f3n, existen opiniones encontradas. Mientras unos autores desaconsejan la vacunaci\u00f3n por motivos de seguridad, a menos que en el lactante sean indetectables los niveles de los agentes terap\u00e9uticos utilizados95,96,97,98,99,100, otros no aprecian inconvenientes en administrar dicha vacuna al no haber detectado efectos adversos significativos e incluso argumentan que es m\u00e1s segura que el padecimiento de la enfermedad natural101. En cuanto a la vacunaci\u00f3n del lactante cuya madre recibi\u00f3 inmunosupresores para evitar el rechazo por trasplante de \u00f3rganos, una peque\u00f1a serie no encontr\u00f3 diferencias en los efectos adversos respecto a los que no recibieron vacuna102.\nRecomendaciones\n- Se recomienda la vacunaci\u00f3n frente a rotavirus en lactantes nacidos entre la semana 25-27 (seg\u00fan la vacuna utilizada) y 32 de gestaci\u00f3n, cl\u00ednicamente estables y sin contraindicaciones. La vacunaci\u00f3n se realizar\u00e1 a partir de las 6 semanas de vida seg\u00fan la edad cronol\u00f3gica y siguiendo las pautas autorizadas para cada vacuna.\n(Se considera cl\u00ednicamente estable cuando se encuentra en fase de crecimiento sostenido, sin necesidad de ventilaci\u00f3n mec\u00e1nica ni terapia esteroidea o para infecciones graves, sin alteraciones metab\u00f3licas, cardiovasculares o respiratorias significativas).\n- En otras situaciones de prematuridad diferentes a las se\u00f1aladas anteriormente se valorar\u00e1 la vacunaci\u00f3n de manera individualizada.\n- Tras la vacunaci\u00f3n se realizar\u00e1n las medidas est\u00e1ndar de prevenci\u00f3n primaria de transmisi\u00f3n del virus vacunal, sobre todo en las primeras 2 semanas tras la vacunaci\u00f3n. Estas medidas se extremar\u00e1n en caso de administraci\u00f3n de la vacuna frente a rotavirus en el medio hospitalario.\n- Dada la excepcionalidad de la enfermedad grave o muy grave en nuestro medio, no se recomienda, con car\u00e1cter general, la vacunaci\u00f3n frente a rotavirus en prematuros cuyas madres recibieron medicamentos inmunosupresores durante el embarazo. La vacunaci\u00f3n se podr\u00eda considerar dependiendo del f\u00e1rmaco utilizado y del tiempo transcurrido desde la finalizaci\u00f3n del tratamiento, en base a la evidencia cient\u00edfica disponible en cada caso.\n[6.\nGripe ]\nDiferentes estudios han relacionado la prematuridad, particularmente aquellos casos con complicaciones cardiopulmonares, con un mayor riesgo de morbilidad y hospitalizaci\u00f3n por gripe103. En concreto, la infecci\u00f3n gripal en los prematuros se ha asociado con un mayor riesgo significativo de ingreso en UCI o mortalidad (OR: 2,8; IC95%: 1,01-6,9)104. Estudios realizados durante la gripe pand\u00e9mica de 2009 mostraron que el 35 % de menores de 1 a\u00f1o ingresados por complicaciones asociadas a la gripe en las unidades neonatales hospitalarias hab\u00edan nacido prematuros y que, del total de los ingresados menores de 12 meses, el 9 % fallecieron105.\nEn un estudio de casos y controles en el que se valoraba la asociaci\u00f3n entre ciertas caracter\u00edsticas de la poblaci\u00f3n infantil de 6-59 meses y su entorno con el riesgo de hospitalizaci\u00f3n por complicaciones de gripe, se encontr\u00f3 una asociaci\u00f3n significativa (p <0,003) con el bajo peso al nacer106.\nUn reciente metaan\u00e1lisis, publicado en 2015, dise\u00f1ado para detectar en la poblaci\u00f3n infantil factores relacionados con las complicaciones por gripe o enfermedad gripal, que consider\u00f3 como complicaci\u00f3n la hospitalizaci\u00f3n por gripe, encontr\u00f3 una potente asociaci\u00f3n con la prematuridad (OR 4,33; IC95%: 2,47-\n7,58)107.\nAunque los neonatos prematuros pueden desarrollar respuestas inmunitarias inferiores respecto a los nacidos a t\u00e9rmino, las respuestas de anticuerpos tras vacunaci\u00f3n antigripal entre los 6 y los 48 meses de edad, medidas por inhibici\u00f3n de la hemaglutinaci\u00f3n, mostraron una media geom\u00e9trica de t\u00edtulos de anticuerpos con niveles protectores independientemente de la EG108,109.\nDiferentes estudios en prematuros nacidos con EG \u226432 semanas y peso \u22641500 g, con 6-17 meses de edad y previamente no vacunados, han detectado buena respuesta inmune frente a diferentes cepas vacunales tras dos dosis de vacuna antigripal inactivada trivalente (TIV). Los t\u00edtulos de anticuerpos posvacunales (medidos por inhibici\u00f3n de hemaglutinaci\u00f3n) son similares a los lactantes a t\u00e9rmino a los 56 d\u00edas y 9 meses despu\u00e9s de ser vacunados110,111,112.\nHay pocos estudios con datos de efectividad de la vacunal antigripal en prematuros y, en algunos, la efectividad encontrada es muy baja por falta de potencia estad\u00edstica113. Un estudio en Australia en 2016, realizado en la poblaci\u00f3n infantil de 6-59 meses de edad que acudi\u00f3 a urgencias entre 2008-2014 con diagn\u00f3stico confirmado de gripe y que hab\u00edan recibido vacuna antigripal (TIV), compar\u00f3 los prematuros (<37 semanas de gestaci\u00f3n, n=344) completa o parcialmente vacunados de gripe frente a los no vacunados. No se observaron infecciones gripales en los prematuros completamente vacunados y, al comparar los prematuros total y parcialmente vacunados con los no vacunados, se observ\u00f3 una efectividad vacunal ajustada del 79,2 % (IC95%: 10,9 - 95,1)114.\nLos escasos estudios de seguridad de las vacunas muestran un buen perfil109. No se observaron diferencias significativas en los efectos adversos observados en el grupo de reci\u00e9n nacidos prematuros tras el uso de vacuna adyuvada de gripe pand\u00e9mica monovalente de 2009 A/H1N1 MF59115.\nDiferentes pa\u00edses incluyen recomendaciones de vacunaci\u00f3n antigripal en poblaci\u00f3n infantil a partir de los 6 meses de edad, independientemente de la EG70,72,116,117,118,119.\nDos pa\u00edses recomiendan espec\u00edficamente la vacuna antigripal para reci\u00e9n nacidos prematuros, Nueva Zelanda a partir de los 6 meses de edad a los prematuros que desarrollan enfermedad pulmonar cr\u00f3nica120 e Israel a todos los prematuros a partir de los 6 meses de edad121.\nDestacar que las fichas t\u00e9cnicas de las vacunas antigripales establecen los seis meses como edad m\u00ednima para poder recibir la vacuna, pero existen diferentes estudios que refieren una buena respuesta inmunitaria y seguridad en lactantes de 6-12 semanas de edad122,123 o 10-22 semanas124.\nAdem\u00e1s de la inmunizaci\u00f3n activa mediante vacunaci\u00f3n, la gripe en prematuros puede prevenirse mediante la vacunaci\u00f3n en embarazadas, recomendada en Espa\u00f1a en cualquier trimestre de gestaci\u00f3n45. La evidencia actual demuestra la seguridad de la vacunaci\u00f3n antigripal en embarazadas, no habi\u00e9ndose detectado patrones inusuales en las complicaciones del embarazo en las gestantes que recibieron vacunas antigripales125, incluida la no asociaci\u00f3n con riesgo de parto prematuro126. Asimismo, la efectividad de esta medida para reducir el riesgo de gripe confirmada por laboratorio en mujeres embarazadas y en los reci\u00e9n nacidos menores de 6 meses, proporciona una protecci\u00f3n previa al momento en que se puede iniciar la vacunaci\u00f3n del reci\u00e9n nacido prematuro127,128,129.\nRecomendaciones\n- Se considera que los prematuros de menos de 32 semanas de gestaci\u00f3n tienen alto riesgo de complicaciones tras una gripe, por lo que se recomienda la vacunaci\u00f3n antigripal anual entre los 6 y los 24 meses de edad. En caso de presentar alg\u00fan factor de riesgo, se continuar\u00e1 con la vacunaci\u00f3n anual tras los 24 meses de edad.\n- Pauta de vacunaci\u00f3n: la primera vez que se vacunen se administrar\u00e1n 2 dosis de vacuna antigripal (0,5 ml) separadas con un intervalo m\u00ednimo de 4 semanas entre dosis. En vacunaciones posteriores se administrar\u00e1 1 dosis.\n- Esta estrategia de vacunaci\u00f3n de prematuros se complementa con la recomendaci\u00f3n, ya vigente en nuestro pa\u00eds, de vacunaci\u00f3n con una dosis de vacuna inactivada a embarazadas en cualquier trimestre de gestaci\u00f3n.\n- Los convivientes con ni\u00f1os y ni\u00f1as con antecedente de prematuridad, de cualquier edad y hasta que estos menores alcancen la edad de 24 meses, deber\u00e1n vacunarse anualmente frente a la gripe.\n[7.\nSeguridad de las vacunas ]\nEs de especial importancia la reactogenicidad de la vacunaci\u00f3n en el grupo de poblaci\u00f3n de prematuros. En una revisi\u00f3n reciente sobre la seguridad de las vacunas en prematuros se observa que, en general, las vacunas presentan un perfil de seguridad similar a la observada en los nacidos a t\u00e9rmino4. Sin embargo, en los prematuros <28 semanas de EG o <1 500 g, o incluso aquellos que padecieron sepsis, se han observado diversos eventos cardiorrespiratorios, como episodios de apnea, desaturaci\u00f3n y bradicardia durante las 48-72 horas siguientes a la vacunaci\u00f3n, si bien estos fen\u00f3menos suelen ser transitorios, resolvi\u00e9ndose espont\u00e1neamente o con m\u00ednima intervenci\u00f3n, como oxigenoterapia nasal ligera4.\nAunque en algunos estudios relacionaban estos episodios cardiorrespiratorios con la vacuna frente a tosferina de c\u00e9lulas completas130,131,132, en otros no se observaron diferencias en la utilizaci\u00f3n de esta vacuna con la acelular133,134, implicando m\u00e1s a la existencia de episodios de apnea previos a la vacunaci\u00f3n135 y el peso inferior a 2 000 gramos133,135.\nPor otro lado, algunos autores, tras la realizaci\u00f3n de estudios prospectivos de alta calidad, no est\u00e1n de acuerdo con que las vacunas sean las responsables de los fen\u00f3menos cardiorrespiratorios y abogan por la monitorizaci\u00f3n posvacunal solo en prematuros con inestabilidad cardiorrespiratoria4,47,134,136.\nDe todas formas, por prudencia, en los grandes prematuros (EG <32 semanas) se recomienda la monitorizaci\u00f3n tras la vacunaci\u00f3n y, cuando precisen la administraci\u00f3n de vacunas durante su hospitalizaci\u00f3n, se aconseja la monitorizaci\u00f3n cardiorrespiratoria durante las 72 horas posvacunaci\u00f3n, sobre todo en aquellos con antecedentes de apneas o inestabilidad cardiovascular, en aquellos con peso en ese momento inferior a 2000 gramos y en los que nacieron con menos de 28 semanas.\n[8. Recomendaciones\n]\n- La vacunaci\u00f3n infantil en nacidos con prematuridad (antes de la semana 37) se realizar\u00e1 seg\u00fan la edad cronol\u00f3gica, comenzando la vacunaci\u00f3n a los 2 meses de edad (posnatal), independientemente de su edad gestacional o peso al nacer.\n- Tras la revisi\u00f3n del riesgo de tosferina, hepatitis B y\nenfermedad invasiva por H. influenzae\ntipo b y neumococo en prematuros, as\u00ed como de la respuesta de esta poblaci\u00f3n a\nla vacunaci\u00f3n, no parece necesario modificar la actual pauta de vacunaci\u00f3n 2+1\nque se utiliza para los lactantes nacidos a t\u00e9rmino. Tambi\u00e9n se mantendr\u00e1 la\npauta 1+1 en el caso de meningococo, a los 4 y 12 meses de edad. La protecci\u00f3n\ncomunitaria generada por las altas coberturas de vacunaci\u00f3n infantil apoya esta\nrecomendaci\u00f3n.\n- Es de capital importancia la vacunaci\u00f3n \u201cen tiempo\u201d en el momento de cumplir la edad establecida (comenzando el d\u00eda que se cumplen los dos meses de vida) o lo antes posible tras ese momento.\n- Para prevenir la tosferina en los lactantes prematuros en los 2-3 primeros meses de vida, es recomendable la vacunaci\u00f3n de embarazadas con dTpa a partir de la semana 27, pero preferentemente en la semana 27 o 28, incrementando en lo posible las coberturas actuales.\nEn embarazadas con alto riesgo de parto prematuro y cl\u00ednicamente estables se puede valorar la vacunaci\u00f3n a partir de la semana 20 de gestaci\u00f3n.\n- Para evitar la infecci\u00f3n perinatal por el virus de la hepatitis B en reci\u00e9n nacidos de madre portadora o madre sin cribado prenatal, se recomienda la administraci\u00f3n, en las primeras 12 horas de vida, de vacuna monocomponente de hepatitis B y de la inmunoglobulina hiperinmune anti-hepatitis B. Se continuar\u00e1 la pauta con vacuna hexavalente como en el resto de la poblaci\u00f3n infantil, sin que sea preciso tener en cuenta el peso al nacer.\n- Se recomienda la vacunaci\u00f3n frente a rotavirus a partir\nde las 6 semanas de vida en lactantes nacidos entre la semana 25-27 (seg\u00fan\nvacuna utilizada) y 32 de gestaci\u00f3n, cl\u00ednicamente estables y sin\ncontraindicaciones. La vacunaci\u00f3n se realizar\u00e1 seg\u00fan edad cronol\u00f3gica y\nsiguiendo las pautas autorizadas para cada vacuna. En otras situaciones de\nprematuridad diferentes a las se\u00f1aladas anteriormente se valorar\u00e1 la vacunaci\u00f3n\nde manera individualizada.\n- Tras la vacunaci\u00f3n se realizar\u00e1n las medidas est\u00e1ndar de prevenci\u00f3n primaria de transmisi\u00f3n del virus vacunal, sobre todo en las primeras 2 semanas. Estas medidas se extremar\u00e1n en caso de administraci\u00f3n de la vacuna frente a rotavirus en el medio hospitalario.\n- Dada la excepcionalidad de la enfermedad grave o muy grave en nuestro medio, no se recomienda, con car\u00e1cter general, la vacunaci\u00f3n frente a rotavirus en prematuros cuyas madres recibieron anticuerpos monoclonales y f\u00e1rmacos como etanercept con efecto inmunosupresor durante el embarazo. La vacunaci\u00f3n se podr\u00eda considerar dependiendo del agente terap\u00e9utico utilizado y del tiempo transcurrido desde la finalizaci\u00f3n del tratamiento, en base a la evidencia cient\u00edfica disponible en cada caso.\n- Los prematuros de menos de 32 semanas de gestaci\u00f3n se\nconsideran de alto riesgo para las complicaciones de la gripe y se recomienda\nla administraci\u00f3n de vacuna antigripal inactivada entre los 6 y los 24 meses de\nedad. En caso de presentar alg\u00fan factor de riesgo, se continuar\u00e1 con la vacunaci\u00f3n\nanual tras los 24 meses de edad.\n- La primera vez que se vacunen se administrar\u00e1n 2 dosis de vacuna antigripal de 0,5 ml separadas con un intervalo m\u00ednimo de 4 semanas entre dosis. En vacunaciones posteriores se administrar\u00e1 1 dosis.\n- Esta estrategia de vacunaci\u00f3n de prematuros se complementa con la recomendaci\u00f3n vigente de vacunaci\u00f3n embarazadas con una dosis de vacuna inactivada en cualquier trimestre de la gestaci\u00f3n.\n- Los convivientes con ni\u00f1os y ni\u00f1as con antecedente de prematuridad, de cualquier edad y hasta que estos menores alcancen la edad de 24 meses, deber\u00e1n vacunarse anualmente frente a la gripe.\n- Se recuerda que el personal sanitario que contacta con prematuros debe estar adecuadamente vacunado seg\u00fan las recomendaciones vigentes45.\n[9.\nBibliograf\u00eda ]\n1\nInstituto Nacional de\nEstad\u00edstica. Nacimientos. A\u00f1o 2017. Disponible en\n[www.ine.es](http://www.ine.es/) [[](http://www.ine.es/)consultado el 31 de octubre\nde 2019]. 2\nHarrison MS, Goldenberg RL. Global burden of prematurity. Semin Fetal Neonatal Med 2016; 21(2): 74-79.\n3\nMartin LJ, Sj\u00f6rs G, Reichman B, et al. and International Network for Evaluating Outcomes (iNeo) of Neonates Investigators. Country-specific vs. common birthweight-for gestational age references to identify small for gestational age infants born at 24-28 weeks: An international study. Paediatr Perinat Epidemiol 2016; 30(5): 450461. 4\nChiappini E, Petrolini C, Sandini E, et al. Update on vaccination of preterm infants: a systematic review about safety and efficacy/effectiveness. Proposal for a position statement by Italian Society of Pediatric Allergology and Immunology jointly with the Italian Society of Neonatology. Expert Rev Vaccines 2019; 18(5):523-545.\n5\nRiise \u00d8R, Laake I, Vestrheim D, et al. Preterm children have higher risk than full-term children of invasive pneumococcal disease during the first 2 years of life. Pediatr Infect Dis J 2018; 37(7): e195-e200.\n6\nMalek A, Sager R, Kuhn P et al. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 1996; 36: 248-255.\n[Baxter D.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Baxter%20D%5BAuthor%5D&cauthor=true&cauthor_uid=20519937) Impaired\nfunctioning of immune defenses to infection in premature and term infants and\ntheir implications for vaccination. [Hum Vaccin](https://www.ncbi.nlm.nih.gov/pubmed/20519937) [Bednarek A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bednarek%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30033997) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bednarek%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30033997) [Bartkowiak](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bartkowiak-Emeryk%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30033997) [-](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bartkowiak-Emeryk%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30033997) [Emeryk M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bartkowiak-Emeryk%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30033997) [, ](https://www.ncbi.nlm.nih.gov/pubmed/?term=Klepacz%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30033997) [Klepacz R,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Klepacz%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30033997) et al.\nPersistence of vaccine-induced immunity in preschool children: Effect of\ngestational age. [Med Sci Monit](https://www.ncbi.nlm.nih.gov/pubmed/30033997)\n9\nFerreira CSM, Perin MCAA, Moraes-Pinto MI, et al. Humoral immune response to measles and varicella vaccination in former very low birth weight preterm infant. Braz J Infect Dis 2018; 22(1): 41-46.\n10\nFerreira CSM, Perin MCAA, Moraes-Pinto MI, et al. Humoral immune response to measles and varicella vaccination in former very low birth weight preterm infant. Braz J Infect Dis 2018; 22(1): 41-46.\n11\nPall\u00e1s Alonso C, Garc\u00eda Gonz\u00e1lez P, Jimenez Moya A, et al; en representaci\u00f3n del Grupo de Seguimiento de la Sociedad Espa\u00f1ola de Neonatolog\u00eda. Protocolo de seguimiento para el reci\u00e9n nacido menor de 1.500 g o menor de 32 semanas de edad gestaci\u00f3n. An Pediatr (Barc) 2018; 88(4): 229.e1-229.e10.\n12\nGrupo de trabajo de la Ponencia de Programa y Registro de Vacunaciones. Revisi\u00f3n del Calendario de Vacunaci\u00f3n. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, Servicios Sociales e Igualdad, marzo 2016. Disponible en:\n[http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Revision_CalendarioVac\n](http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Revision_CalendarioVacunacion.pdf) [unacion.pdf](http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Revision_CalendarioVacunacion.pdf)\n13\nLaforgia N, Di Mauro A, Bianchi FP, et al. Are pre-terms born timely and right immunized? Results of an Italian cohort study. Hum Vaccin Immunother 2018; 14(6): 1398-1402.\n14\n[Hofstetter AM](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hofstetter%20AM%5BAuthor%5D&cauthor=true&cauthor_uid=31391213) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hofstetter%20AM%5BAuthor%5D&cauthor=true&cauthor_uid=31391213) [Jacobson EN](https://www.ncbi.nlm.nih.gov/pubmed/?term=Jacobson%20EN%5BAuthor%5D&cauthor=true&cauthor_uid=31391213) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Jacobson%20EN%5BAuthor%5D&cauthor=true&cauthor_uid=31391213) [deHart MP,](https://www.ncbi.nlm.nih.gov/pubmed/?term=deHart%20MP%5BAuthor%5D&cauthor=true&cauthor_uid=31391213) et al. Early\nchildhood vaccination status of preterm infants. [Pediatrics](https://www.ncbi.nlm.nih.gov/pubmed/?term=Early+Childhood+Vaccination+Status+of+Preterm+Infants)\n15\nLangkamp D, Davis J. Increased risk of reported pertussis and hospitalization associated with pertussis in low birth weight children. J Pediatr 1996; 128: 654-659.\n16\nHviid A. Effectiveness of two pertussis\nvaccines in preterm Danish children. Vaccine 2009; 27: 3035-3038.\n17\nMarshall H, Clarke M, Rasiah K et al. Predictors of disease severity in children hospitalized for pertussis during an epidemic. Pediatr Infect Dis J 2015; 34: 339-345. 18\nRiise O, Laake I, Verstrheim D et al. Risk of pertussis in relation to degree of prematurity in children less tan 2 years of age. Pediatr Infect Dis J 2017; 36: 151-156. 19\nWarfel J, Zimmerman L, Merkel T. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. PNAS 2014; 111: 787-792.\n20\nSlack M, Cade S, Schapira D et al. DT5aP-Hib-IPV and MCC vaccine: preterm infants\u00b4s response to accelerated immunisation. Arch Dis Child 2005; 90: 338-341.\n21\nOme\u00f1aca F, Garc\u00eda-Sicilia J, Garc\u00eda-Corbeira P et al. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics 2005; 116: 1292-1298.\n22\nFaldella G, Alessandroni R, Magini G et al. The preterm infant\u00b4s antibody response to a combined diphtheria, tetanus, acellular pertussis and hepatitis B vaccine. Vaccine 1998; 16: 1646-1649.\n23\nSchloesser R, Fischer D, Otto W et al. Safety and immunogenicity of an acellular pertussis vaccine in premature infants. Pediatrics 1999; 103: e60. 24\nVermeulen F, Dirix V, Verscheure V et al. Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three different vaccines and effect of a booster dose. Vaccine 2013; 31: 1981-1986.\n25\nV\u00e1zquez L, Garc\u00eda F, R\u00fctimann R et al. Immunogenicity and reactogenicty of DTPa-HBV-IPV/Hib vaccine as primary and booster vaccination in low-birth-weight premature infants. Acta Paediatr 2008; 97: 1243-1249.\n26\nEsposito S, Faldella G, Gianmanco A et al. Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in preterms infants. Vaccine 2002; 20:\n2928-2932.\n27\nOffice F\u00e9deral de la Sant\u00e9 Publique OFSP. Plan de vaccination Suisse 2019. Disponible en:\n[https://www.infovac.ch/docs/public/fs/plan](https://www.infovac.ch/docs/public/fs/plan-de-vaccination-2019.pdf) [-](https://www.infovac.ch/docs/public/fs/plan-de-vaccination-2019.pdf) [de](https://www.infovac.ch/docs/public/fs/plan-de-vaccination-2019.pdf) [-](https://www.infovac.ch/docs/public/fs/plan-de-vaccination-2019.pdf) [vaccination](https://www.infovac.ch/docs/public/fs/plan-de-vaccination-2019.pdf) [-](https://www.infovac.ch/docs/public/fs/plan-de-vaccination-2019.pdf) [2019.pdf](https://www.infovac.ch/docs/public/fs/plan-de-vaccination-2019.pdf)\n28\nAustralian Government. Department of Health. National Immunisation Program Schedule. Disponible en:\n[https://beta.health.gov.au/health](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [-](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [topics/immunisation/immunisation](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [-](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [throughout](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [-](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [life/national](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [-](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [immunisation](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [program](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [-](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [schedule#national](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [-](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [immunisation](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [-](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [program](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [-](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [schedule](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [-](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [from](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [-](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [1](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [-](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [april](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [-](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019) [2019](https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019)\nVilajeliu A, Gonc\u00e9 A, L\u00f3pez M et al. Combined tetanus-diphtheria and pertussis vaccine during pregnancy: transfer of maternal pertussis antibodies to the newborn. Vaccine 2015; 33: 1056-1062.\n30\nSimister N. Placental transport of immunoglobulin. Vaccine 2003; 21: 3365-3369.\n31\nKohler P, Farr R. Elevation of cord over maternal IgG immunoglobulin: evidence for an active placental IgG transport. Nature 1966; 210: 1070-1071.\n32\nVan den Bergh J, Westerbeek E, Berbers G et al. Transplacental transport of IgG antibodies specific for pertussis, diphtheria, Haemophilus influenzae type b, and Neisseria meningitidis serogroup C is lower in preterm compared with term infants. Pediatr Infect Dis J 2010; 29: 801-805.\n33\nLeuridan E, Hens N, Peeters N et al. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J 2011; 30: 608-610.\n34\nAbu Raya B, Srugo I, Kessel A et al. The effect of timing of maternal tetanus, diphtheria, and acellular pertussis immunization during pregnancy on newborn pertussis antibody levels \u2013 A prospective study. Vaccine 2014; 32:\n5789-5793.\n35\nAbu Raya B, Bamberger E, Almog M et al. Immunization of pregnant women against pertussis: the effect of timing on antibody avidity. Vaccine 2015; 33: 1948-1952.\n36\nHealy M, Rench M, Swaim L et al. Association between third-trimester DTPa immunization and neonatal pertussis antibody concentration. JAMA 2018; 320: 1464-1470.\n37\nEberhardt Ch, Blanchard-Rohner G, Lema\u00eetre B et al. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. Clin Infect Dis 2016; 62: 829-836.\n38\nEberhardt Ch, Blanchard-Rohner G, Lema\u00eetre B et al. Pertussis antibody transfer to preterm neonates after second \u2013 versus third \u2013 trimester maternal immunization. Clin Infect Dis 2017; 64: 1129-1132.\n39\nPublic\nHealth England. Vaccination against pertussis for pregnant women \u2013 2016.\nInformation for healthcare professional. Disponible en:\n[https://www.gov.uk/government/publications/vaccination](https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women) [-](https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women) [against](https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women) [-](https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women) [pertussis](https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women) [whooping](https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women) [-](https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women) [cough](https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women) [-](https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women) [for](https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women) [-](https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women) [pregnant](https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women) [-](https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women) [women](https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women)\n40\nDepartment of Health.\nMeeting minutes of the Joint Committee on Vaccines and Immunization. June 2019.\nDisponible en:\n[https://app.box.com/s/iddfb4ppwkmtjusir2tc/file/492419147748](https://app.box.com/s/iddfb4ppwkmtjusir2tc/file/492419147748)\nLiang JL,\n[Tiwari T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tiwari%20T%5BAuthor%5D&cauthor=true&cauthor_uid=29702631) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tiwari%20T%5BAuthor%5D&cauthor=true&cauthor_uid=29702631) [Moro P,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Moro%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29702631) et al.\nPrevention of pertussis, tetanus, and diphtheria with vaccines in the United\nStates: Recommendations of the Advisory Committee on Immunization Practices\n(ACIP). MMWR 2018; 67: 1-44.\n42\nDarshene Janagaraj P, Shanmuga Raman Gurusamy P, Webby R. Current antenatal pertussis vaccination guidelines miss preterm infants: an epidemiological study from the Northern Territory. Aust N Z J Obstet Gynecol 2019; 59:\n436-443.\n43\nMinisterio de Sanidad, Servicios Sociales e\nIgualdad. Adenda actualizaci\u00f3n en \u201cRevisi\u00f3n del Programa de Vacunaci\u00f3n frente a\nla Tosferina en Espa\u00f1a. Junio 2015. Disponible en:\n[http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/difteria_tetano_tosferina.ht\n](http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/difteria_tetano_tosferina.htm) [m](http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/difteria_tetano_tosferina.htm)\n44\nDe Schutter S, Maertens K, Baerts L et al. Quantification of vaccine-induced antipertussis toxin secretory IgA antibodies in breast milk. Pediatr Infect Dis J 2015; 34: e149-e152.\n45\nGrupo de trabajo vacunaci\u00f3n en poblaci\u00f3n adulta y grupos de riesgo de la Ponencia de Programa y Registro de\nVacunaciones. Vacunaci\u00f3n en grupos de riesgo de todas las edades y en determinadas situaciones. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, Consumo y Bienestar Social, julio 2018. Disponible en:\n[http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/VacGruposRiesgo/Vac_Grup\n](http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/VacGruposRiesgo/Vac_GruposRiesgo_todasEdades.htm) [osRiesgo_todasEdades.htm](http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/VacGruposRiesgo/Vac_GruposRiesgo_todasEdades.htm)\n46\nWorld Health Organization. The immunological basis for immunization series: module 22: hepatitis B. Disponible en:\n[https://apps.who.int/iris/bitstream/handle/10665/77755/9789241504751_eng.pdf;jsessionid=272BC1A4661C430\n](https://apps.who.int/iris/bitstream/handle/10665/77755/9789241504751_eng.pdf;jsessionid=272BC1A4661C4301E04A0AD63466C6CA?sequence=1) [1E04A0AD63466C6CA?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/77755/9789241504751_eng.pdf;jsessionid=272BC1A4661C4301E04A0AD63466C6CA?sequence=1)\n47\nEsposito S, Fumagalli M, Principi N. Immunogenicity, safety and tolerability of vaccinations in premature infants. Expert Rev Vaccines 2012; 11(10): 1199-1209.\n48\nLau Y, Tam A, Ng K, et al. Response of preterm infants to hepatitis B vaccine. J Pediatr 1992; 121: 962-965.\n49\nMast E, Margolis H, Fiore A et al A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54(RR-16):1-31.\n50\nLosonsky G, Wasserman S, Stephens I, et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics 1999; 103: E14\u201420\n51\nSchillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States:\nRecommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018; 67(No. RR1): 1\u201331. 52\nWorld Health Organization.\n[Hepatitis B vaccines: WHO position paper ](https://www.ncbi.nlm.nih.gov/pubmed/28685564) [\u2013 ](https://www.ncbi.nlm.nih.gov/pubmed/28685564) [July 2017.](https://www.ncbi.nlm.nih.gov/pubmed/28685564) [W](https://www.ncbi.nlm.nih.gov/pubmed/28685564)kly Epidemiol Rec 2017; 92(27): 369-392.\n53\nComit\u00e9 Asesor de\nVacunas (CAV-AEP). Hepatitis B. Manual de vacunas en l\u00ednea de la AEP\n[Internet]. Madrid: AEP; jun/2019. Disponible en:\n[http://vacunasaep.org/documentos/manual/cap](http://vacunasaep.org/documentos/manual/cap-29) [-](http://vacunasaep.org/documentos/manual/cap-29) [29](http://vacunasaep.org/documentos/manual/cap-29) [[](http://vacunasaep.org/documentos/manual/cap-29)consultado el 31 de octubre de 2019]. 54 [Tr\u00fcck J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tr%C3%BCck%20J%5BAuthor%5D&cauthor=true&cauthor_uid=20851537) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tr%C3%BCck%20J%5BAuthor%5D&cauthor=true&cauthor_uid=20851537) [Pollard AJ.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pollard%20AJ%5BAuthor%5D&cauthor=true&cauthor_uid=20851537) Challenges\nin immunisation against bacterial infection in children. [Early Hum Dev](https://www.ncbi.nlm.nih.gov/pubmed/?term=preterm+infants+and+invasive+disease%2C+meningococcal%2C+haemophilus+influenzae) [2](https://www.ncbi.nlm.nih.gov/pubmed/?term=preterm+infants+and+invasive+disease%2C+meningococcal%2C+haemophilus+influenzae)010; 86(11): 695-701.\n55\n[Okike IO](https://www.ncbi.nlm.nih.gov/pubmed/?term=Okike%20IO%5BAuthor%5D&cauthor=true&cauthor_uid=24997051) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Okike%20IO%5BAuthor%5D&cauthor=true&cauthor_uid=24997051) [Johnson AP](https://www.ncbi.nlm.nih.gov/pubmed/?term=Johnson%20AP%5BAuthor%5D&cauthor=true&cauthor_uid=24997051) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Johnson%20AP%5BAuthor%5D&cauthor=true&cauthor_uid=24997051) [Henderson KL,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Henderson%20KL%5BAuthor%5D&cauthor=true&cauthor_uid=24997051) et al.\nIncidence, etiology, and outcome of bacterial meningitis in infants aged <90\ndays in the United kingdom and Republic of Ireland: prospective, enhanced,\nnational population-based surveillance. [Clin Infect Dis](https://www.ncbi.nlm.nih.gov/pubmed/24997051) [2](https://www.ncbi.nlm.nih.gov/pubmed/24997051)014; 59(10): e150-157.\n56\n[Gagneur A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gagneur%20A%5BAuthor%5D&cauthor=true&cauthor_uid=26291883) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gagneur%20A%5BAuthor%5D&cauthor=true&cauthor_uid=26291883) [Pinquier D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pinquier%20D%5BAuthor%5D&cauthor=true&cauthor_uid=26291883) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pinquier%20D%5BAuthor%5D&cauthor=true&cauthor_uid=26291883) [Quach C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Quach%20C%5BAuthor%5D&cauthor=true&cauthor_uid=26291883) [.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Quach%20C%5BAuthor%5D&cauthor=true&cauthor_uid=26291883) [Immunization of preterm infants.](https://www.ncbi.nlm.nih.gov/pubmed/26291883) [Hum Vaccin Immunother](https://www.ncbi.nlm.nih.gov/pubmed)\n57\n[Kent A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kent%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30281069) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kent%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30281069) [Makwana A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Makwana%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30281069) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Makwana%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30281069) [Sheppard CL,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sheppard%20CL%5BAuthor%5D&cauthor=true&cauthor_uid=30281069) et al.\nInvasive pneumococcal disease in UK children <1 year of age in the\npost13-valent pneumococcal conjugate vaccine era: what are the risks now?. [Clin Infect Dis](https://www.ncbi.nlm.nih.gov/pubmed/30281069)\n58\n[Yildirim I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yildirim%20I%5BAuthor%5D&cauthor=true&cauthor_uid=30281070) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yildirim%20I%5BAuthor%5D&cauthor=true&cauthor_uid=30281070) [Pelton SI.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pelton%20SI%5BAuthor%5D&cauthor=true&cauthor_uid=30281070) Infants at\nrisk for invasive pneumococcal disease in the 13-valent pneumococcal conjugate\nvaccine era. [Clin Infect Dis](https://www.ncbi.nlm.nih.gov/pubmed/30281070)\n59\nSzynczewska E, Chlebna-Soko D. Immunogenicity of heptavalent conjugate vaccine against streptococcus pneumoniae in premature babies with low birth weight. Pediatrics and Neonatology 2014; 55: 101-107.\n60\nKent A, Ladhani SN, Andrews NJ, et al. Schedules for pneumococcal vaccination of preterm infants: an RCT. Pediatrics 2016; 138: e20153945-56.\n61\n[Martin\u00f3n](https://www.ncbi.nlm.nih.gov/pubmed/?term=Martin%C3%B3n-Torres%20F%5BAuthor%5D&cauthor=true&cauthor_uid=27902652) [-](https://www.ncbi.nlm.nih.gov/pubmed/?term=Martin%C3%B3n-Torres%20F%5BAuthor%5D&cauthor=true&cauthor_uid=27902652) [Torres F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Martin%C3%B3n-Torres%20F%5BAuthor%5D&cauthor=true&cauthor_uid=27902652) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Martin%C3%B3n-Torres%20F%5BAuthor%5D&cauthor=true&cauthor_uid=27902652) [Wysocki J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wysocki%20J%5BAuthor%5D&cauthor=true&cauthor_uid=27902652) [, ](https://www.ncbi.nlm.nih.gov/pubmed/?term=Center%20KJ%5BAuthor%5D&cauthor=true&cauthor_uid=27902652) [Center KJ,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Center%20KJ%5BAuthor%5D&cauthor=true&cauthor_uid=27902652) et al.\nCirculating antibody 1 and 2 years after vaccination with the 13valent\npneumococcal conjugate vaccine in preterm compared with term infants. [Pediatr Infect Dis J](https://www.ncbi.nlm.nih.gov/pubmed/27902652)\n326-332.\n62\nKristensen K, Gyhrs A, Lausen B, et al. Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. Pediatr Infect Dis J 1996; 15: 525-529.\n63\nTsuda K, Iwasaki S, Horiguchi H, et al. Immune response to Haemophilus influenzae type b conjugate vaccine in preterm infants. Pediatr Int 2012; 54: 64-67. 64\n[Ome\u00f1aca F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ome%C3%B1aca%20F%5BAuthor%5D&cauthor=true&cauthor_uid=29336924) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ome%C3%B1aca%20F%5BAuthor%5D&cauthor=true&cauthor_uid=29336924) [V\u00e1zquez L](https://www.ncbi.nlm.nih.gov/pubmed/?term=V%C3%A1zquez%20L%5BAuthor%5D&cauthor=true&cauthor_uid=29336924) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=V%C3%A1zquez%20L%5BAuthor%5D&cauthor=true&cauthor_uid=29336924) [Garcia](https://www.ncbi.nlm.nih.gov/pubmed/?term=Garcia-Corbeira%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29336924) [-](https://www.ncbi.nlm.nih.gov/pubmed/?term=Garcia-Corbeira%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29336924) [Corbeira P,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Garcia-Corbeira%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29336924) et al.\nImmunization of preterm infants with GSK's hexavalent combined\ndiphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate\nvaccine: A review of safety and immunogenicity. [Vaccine](https://www.ncbi.nlm.nih.gov/pubmed/?term=omenaca+immunization+preterm+infants+with+GSK+2018)\n65\nInvasive Haemophilus\ninfluenzae disease. Surveillance Atlas of Infectious Diseases. ECDC;\n[https://atlas.ecdc.europa.eu/public/index.aspx](https://atlas.ecdc.europa.eu/public/index.aspx) [[](https://atlas.ecdc.europa.eu/public/index.aspx)consultado el 31 de octubre de 2019].\n66\nEsposito S, Pugni L, Bosis S, et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre-and full-term infants. Vaccine 2005; 23: 1703-1708.\n67\nOme\u00f1aca F, Ar\u00edstegui J, Tejedor JC, et al. Combined Haemophilus Influenzae type b-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines. Pediatr Infect Dis J 2011; 30: e216-24.\n68\nGrupo de trabajo vacunaci\u00f3n frente a EMI de la Ponencia de Programa y Registro de Vacunaciones.\nRecomendaciones de vacunaci\u00f3n frente a enfermedad meningoc\u00f3cica invasiva. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, Consumo y Bienestar Social, marzo 2019. Disponible en:\n[http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Recomendaciones_Vac\n](http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Recomendaciones_Vacunacion_Meningococo.pdf) [unacion_Meningococo.pdf](http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Recomendaciones_Vacunacion_Meningococo.pdf)\n69\n[Wili\u0144ska M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wili%C5%84ska%20M%5BAuthor%5D&cauthor=true&cauthor_uid=28216484) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wili%C5%84ska%20M%5BAuthor%5D&cauthor=true&cauthor_uid=28216484) [Warakomska M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Warakomska%20M%5BAuthor%5D&cauthor=true&cauthor_uid=28216484) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Warakomska%20M%5BAuthor%5D&cauthor=true&cauthor_uid=28216484) [G\u0142uszczak](https://www.ncbi.nlm.nih.gov/pubmed/?term=G%C5%82uszczak-Idziakowska%20E%5BAuthor%5D&cauthor=true&cauthor_uid=28216484) [-](https://www.ncbi.nlm.nih.gov/pubmed/?term=G%C5%82uszczak-Idziakowska%20E%5BAuthor%5D&cauthor=true&cauthor_uid=28216484) [Idziakowska E,](https://www.ncbi.nlm.nih.gov/pubmed/?term=G%C5%82uszczak-Idziakowska%20E%5BAuthor%5D&cauthor=true&cauthor_uid=28216484) et al.\nRisk factors for adverse events after vaccinations performed during the initial\nhospitalization of infants born prematurely. [Dev Period Med](https://www.ncbi.nlm.nih.gov/pubmed/28216484)\n70\nEuropean Centre for Disease Prevention and\nControl. Vaccine scheduler. Disponible en:\n[https://vaccine](https://vaccine-schedule.ecdc.europa.eu/) [schedule.ecdc.europa.eu/](https://vaccine-schedule.ecdc.europa.eu/)\n71\nMinist\u00e8re des Solidarit\u00e9s et the la Sant\u00e9.\nCalendrier des vaccinations et recommandations vaccinales 2019. Mars 2019.\nDisponible en:\n[https://solidarites](https://solidarites-sante.gouv.fr/IMG/pdf/calendrier_vaccinal_maj_17avril2019.pdf) [-](https://solidarites-sante.gouv.fr/IMG/pdf/calendrier_vaccinal_maj_17avril2019.pdf) [sante.gouv.fr/IMG/pdf/calendrier_vaccinal_maj_17avril2019.pdf](https://solidarites-sante.gouv.fr/IMG/pdf/calendrier_vaccinal_maj_17avril2019.pdf)\n72\nAustralian Government. Department of Health.\nAustralian Immunisation Handbook. Disponible en:\n[https://immunisationhandbook.health.gov.au/vaccination](https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants) [-](https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants) [for](https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants) [-](https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants) [special](https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants) [-](https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants) [risk](https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants) [-](https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants) [groups/vaccination](https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants) [-](https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants) [for](https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants) [-](https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants) [preterm](https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants) [-](https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants) [infants](https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants)\n73\nGovernment of Canada. Canadian Immunization\nGuide: Part 3 - Vaccination of Specific Populations. Disponible en:\n[https://www.canada.ca/en/public](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [health/services/publications/healthy](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [living/canadian](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [immunization](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [guide](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [part](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [3](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [vaccination](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [specific](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [populations/page](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [5](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [immunization](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [infants](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [born](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html) [prematurely.html](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html)\n74\nPublic Health England. Immunisation of individuals with underlying medical conditions. Disponible en:\n[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/566853/Gree\n](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/566853/Green_Book_Chapter7.pdf) [n_Book_Chapter7.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/566853/Green_Book_Chapter7.pdf)\n75\nHSE. Immunisation Guidelines. Disponible en:\n[https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/immunisationguidelines.html](https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/immunisationguidelines.html)\n76\nStatens Serum Institut. Childhood vaccination programme. August 2019. Disponible en:\n[https://en.ssi.dk/vaccination/the](https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme) [-](https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme) [danish](https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme) [-](https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme) [childhood](https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme) [-](https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme) [vaccination](https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme) [-](https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme) [programme](https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme)\n77\nFinnish Institute for Health and Welfare.\nVaccination programme for children and adolescents. Disponible en:\n[https://thl.fi/en/web/vaccination/national](https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents) [-](https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents) [vaccination](https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents) [-](https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents) [programme/vaccination](https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents) [-](https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents) [programme](https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents) [-](https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents) [for](https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents) [-](https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents) [children](https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents) [-](https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents) [and](https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents) [adolescents](https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents) [[](https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents)consultado el 31 de octubre\nde 2019].\n78\nFHI. Vaccination of preterm infants against\npertussis and pneumococci. Immunogenicity, effectiveness and safety. Disponible\nen:\n[https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination](https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf) [-](https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf) [of](https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf) [-](https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf) [preterm](https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf) [infants](https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf) [-](https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf) [against](https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf) [-](https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf) [pertussis](https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf) [-](https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf) [and](https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf) [-](https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf) [pneumococci_web.pdf](https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf)\n79\nMinistry of Health. Immunisation Handbook 2017. 4 Immunisation of special groups. Disponible en:\n[https://www.health.govt.nz/system/files/documents/publications/immshandbook](https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf) [-](https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf) [4](https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf) [-](https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf) [immunisation](https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf) [-](https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf) [special](https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf) [groups](https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf) [-](https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf) [mar18](https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf) [-](https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf) [v3.pdf](https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf)\n80\n[Goldblatt D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Goldblatt%20D%5BAuthor%5D&cauthor=true&cauthor_uid=29174323) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Goldblatt%20D%5BAuthor%5D&cauthor=true&cauthor_uid=29174323) [Southern J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Southern%20J%5BAuthor%5D&cauthor=true&cauthor_uid=29174323) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Southern%20J%5BAuthor%5D&cauthor=true&cauthor_uid=29174323) [Andrews NJ,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Andrews%20NJ%5BAuthor%5D&cauthor=true&cauthor_uid=29174323) et al.\nPneumococcal conjugate vaccine 13 delivered as one primary and one booster dose\n(1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a\nmulticentre, parallel group randomised controlled trial. [Lancet Infect Dis](https://www.ncbi.nlm.nih.gov/pubmed/29174323)\n81\n[Carter](https://www.ncbi.nlm.nih.gov/pubmed/?term=Carter%20ED%5BAuthor%5D&cauthor=true&cauthor_uid=31375441) [ED](https://www.ncbi.nlm.nih.gov/pubmed/?term=Carter%20ED%5BAuthor%5D&cauthor=true&cauthor_uid=31375441) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Carter%20ED%5BAuthor%5D&cauthor=true&cauthor_uid=31375441) [Tam Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tam%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=31375441) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tam%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=31375441) [Walker N.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Walker%20N%5BAuthor%5D&cauthor=true&cauthor_uid=31375441) Impact of\nvaccination delay on deaths averted by pneumococcal conjugate vaccine: Modeled\neffects in 8 country scenarios. [Vaccine](https://www.ncbi.nlm.nih.gov/pubmed?term=2019%5Bpdat%5D+AND+carter%5Bauthor%5D+AND+Impact+of+vaccination+delay+on+deaths+averted+by+pneumococcal+conjugate+vaccine%3A+Modeled+effects+in+8+country+scenarios&TransSchema=title&cmd=detailssearch)\n82\nCoberturas de vacunaci\u00f3n. Datos estad\u00edsticos, tablas 1, 7 y 8. Disponibles en:\n[http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/coberturas.htm](http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/coberturas.htm)\nNewman RD, Grupp-Phelan J, Shay DK, et al. Perinatal risk factors for infant hospitalization with viral gastroenteritis. Pediatrics 1999; 103(1): E3. 84\nDennehy PH, Cortese MM, Begue RE, et al. A case-control study to determine risk factors for hospitalization for rotavirus gastroenteritis in U.S. children. Pediatr Infect Dis J 2006; 25(12): 1123-1131.\n85\nBruijning-Verhagen P, Quach C, Bonten M. Nosocomial rotavirus infections: a meta-analysis. Pediatrics 2012; 129:\ne1011-e1019.\n86\nCivardi E, Tzialla C, Baldanti F, et al. Viral outbreaks in neonatal intensive care units: what we do not know. Am J Infect Control 2013; 41(10): 854-856. 87\nRotaTeq. Ficha t\u00e9cnica. Agencia Espa\u00f1ola del\nMedicamento y Productos Sanitarios (AEMPS). Disponible en:\n[https://cima.aemps.es/cima/dochtml/ft/06348001/FT_06348001.html](https://cima.aemps.es/cima/dochtml/ft/06348001/FT_06348001.html) [[](https://cima.aemps.es/cima/dochtml/ft/06348001/FT_06348001.html)consultado el 31 de octubre\nde 2019].\n88\nRotarix. Ficha t\u00e9cnica. Agencia Espa\u00f1ola del\nMedicamento y Productos Sanitarios (AEMPS). Disponible en:\n[https://cima.aemps.es/cima/dochtml/ft/05330009/FT_05330009.html](https://cima.aemps.es/cima/dochtml/ft/05330009/FT_05330009.html) [[](https://cima.aemps.es/cima/dochtml/ft/05330009/FT_05330009.html)consultado el 31 de octubre\nde 2019].\n89\nChiu M, Bao C, Sadarangani M. Dilemmas with rotavirus vaccine: the neonate and immunocompromised. Pediatr Infect Dis J 2019; 38 (Suppl 6): S43-S46. 90\nOme\u00f1aca F, Sarlangue J, Szenborn L, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J 2012; 31(5): 487-493.\n91\nDahl RM, Curns AT, Tate JE, et al. Effect of rotavirus vaccination on acute diarrheal hospitalizations among low and very low birth weight US infants, 2001-2015. Pediatr Infect Dis J 2018; 37(8): 817-822.\n92\nBriggs-Steinberg C, Shah S. Rationale for in-Neonatal Intensive Care Unit administration of live, attenuated rotavirus vaccination. Am J Perinatol 2018; 35(14): 1443-1448.\n93\nHiramatsu H, Suzuki R, Nagatani A, et al. Rotavirus vaccination can be performed without viral dissemination in the Neonatal Intensive Care Unit. J Infect Dis 2018; 217(4): 589-596.\n94\n\u00c1lvarez Alde\u00e1n J, Ares Segura S, D\u00edaz Gonz\u00e1lez C, et al. Recomendaciones para la vacunaci\u00f3n frente al ROTAvirus de los reci\u00e9n nacidos PREMaturos (ROTAPREM). An Pediatr 2019; 91(3): 205.e1-205.e7.\n95\nFurer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2019. pii: annrheumdis-2019-215882. [Epub ahead of print]. 96\nMahadevan U, Cucchiara S, Hyams JS, et al. The London Position Statement of the World Congress of\nGastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011; 106(2): 214-223.\n97\n[van der Woude CJ](https://www.ncbi.nlm.nih.gov/pubmed/?term=van%20der%20Woude%20CJ%5BAuthor%5D&cauthor=true&cauthor_uid=25602023) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=van%20der%20Woude%20CJ%5BAuthor%5D&cauthor=true&cauthor_uid=25602023) [Ardizzone S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ardizzone%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25602023) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ardizzone%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25602023) [Bengtson MB,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bengtson%20MB%5BAuthor%5D&cauthor=true&cauthor_uid=25602023) et al. The\nsecond European evidenced-based consensus on\nreproduction\nand pregnancy in inflammatory bowel disease.\n[J Crohns Colitis](https://www.ncbi.nlm.nih.gov/pubmed/?term=J+Crohns+colitis+2014%3B9%3A107-124) [2](https://www.ncbi.nlm.nih.gov/pubmed/?term=J+Crohns+colitis+2014%3B9%3A107-124)015; 9(2): 107-124.\n98\n[Desalermos AP](https://www.ncbi.nlm.nih.gov/pubmed/?term=Desalermos%20AP%5BAuthor%5D&cauthor=true&cauthor_uid=25160668) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Desalermos%20AP%5BAuthor%5D&cauthor=true&cauthor_uid=25160668) [Farraye FA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Farraye%20FA%5BAuthor%5D&cauthor=true&cauthor_uid=25160668) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Farraye%20FA%5BAuthor%5D&cauthor=true&cauthor_uid=25160668) [Wasan SK](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wasan%20SK%5BAuthor%5D&cauthor=true&cauthor_uid=25160668) [.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wasan%20SK%5BAuthor%5D&cauthor=true&cauthor_uid=25160668) Vaccinating the\ninflammatory bowel disease patient. [Expert Rev ](https://www.ncbi.nlm.nih.gov/pubmed/?term=Expert+rev+gastroenterol+hepatol+2014%3B9%3A91-102) [Gastroenterol Hepatol](https://www.ncbi.nlm.nih.gov/pubmed/?term=Expert+rev+gastroenterol+hepatol+2014%3B9%3A91-102) [2](https://www.ncbi.nlm.nih.gov/pubmed/?term=Expert+rev+gastroenterol+hepatol+2014%3B9%3A91-102)015; 9(1): 91-102.\n99\n[Long MD](https://www.ncbi.nlm.nih.gov/pubmed/?term=Long%20MD%5BAuthor%5D&cauthor=true&cauthor_uid=25966839) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Long%20MD%5BAuthor%5D&cauthor=true&cauthor_uid=25966839) [Gulati A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gulati%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25966839) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gulati%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25966839) [Wohl D,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wohl%20D%5BAuthor%5D&cauthor=true&cauthor_uid=25966839) et al.\nImmunizations in pediatric and adult patients with inflammatory bowel disease:\na practical case-based approach. [Inflamm Bowel Dis](https://www.ncbi.nlm.nih.gov/pubmed/?term=inflamm+bowel+dis+2015%3B21%3A1993)\n100\n[Nguyen GC](https://www.ncbi.nlm.nih.gov/pubmed/?term=Nguyen%20GC%5BAuthor%5D&cauthor=true&cauthor_uid=26688268) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Nguyen%20GC%5BAuthor%5D&cauthor=true&cauthor_uid=26688268) [Seow CH](https://www.ncbi.nlm.nih.gov/pubmed/?term=Seow%20CH%5BAuthor%5D&cauthor=true&cauthor_uid=26688268) [2](https://www.ncbi.nlm.nih.gov/pubmed/?term=Seow%20CH%5BAuthor%5D&cauthor=true&cauthor_uid=26688268), [Maxwell C,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Maxwell%20C%5BAuthor%5D&cauthor=true&cauthor_uid=26688268) et al. The\nToronto consensus statements for the management of inflammatory bowel disease\nin pregnancy. [Gastroenterology](https://www.ncbi.nlm.nih.gov/pubmed/?term=gastroenterology+2016%3B150%3A734)\n101\nBerkhout A, Clark JE, Wen SC. In utero exposure to biologic disease-modifying anti-rheumatic drugs and effects to the infant: infectious complications, vaccine response, and safety of live vaccine administration. Expert Rev Vaccines 2019; 18: 495-504.\n102\n[Dinelli MIS](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dinelli%20MIS%5BAuthor%5D&cauthor=true&cauthor_uid=29890028) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dinelli%20MIS%5BAuthor%5D&cauthor=true&cauthor_uid=29890028) [Dos Santos AMN](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dos%20Santos%20AMN%5BAuthor%5D&cauthor=true&cauthor_uid=29890028) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dos%20Santos%20AMN%5BAuthor%5D&cauthor=true&cauthor_uid=29890028) [Weckx](https://www.ncbi.nlm.nih.gov/pubmed/?term=Weckx%20LY%5BAuthor%5D&cauthor=true&cauthor_uid=29890028) [LY,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Weckx%20LY%5BAuthor%5D&cauthor=true&cauthor_uid=29890028) et al. Safe administration\nof rotavirus vaccine in a cohort of infants exposed to immunosuppressive drugs\nduring gestation. [Transpl Infect Dis](https://www.ncbi.nlm.nih.gov/pubmed/29890028) [2](https://www.ncbi.nlm.nih.gov/pubmed/29890028)018; 20(5): e12951.\n103\n[Izurieta HS](https://www.ncbi.nlm.nih.gov/pubmed/?term=Izurieta%20HS%5BAuthor%5D&cauthor=true&cauthor_uid=10648764) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Izurieta%20HS%5BAuthor%5D&cauthor=true&cauthor_uid=10648764) [Thompson WW](https://www.ncbi.nlm.nih.gov/pubmed/?term=Thompson%20WW%5BAuthor%5D&cauthor=true&cauthor_uid=10648764) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Thompson%20WW%5BAuthor%5D&cauthor=true&cauthor_uid=10648764) [Kramarz P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kramarz%20P%5BAuthor%5D&cauthor=true&cauthor_uid=10648764) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kramarz%20P%5BAuthor%5D&cauthor=true&cauthor_uid=10648764) el al. Influenza and the\nrates of hospitalization for respiratory disease among infants and young\nchildren. [N Engl J Med](https://www.ncbi.nlm.nih.gov/pubmed/10648764)\n104\n[Louie JK](https://www.ncbi.nlm.nih.gov/pubmed/?term=Louie%20JK%5BAuthor%5D&cauthor=true&cauthor_uid=21041595) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Louie%20JK%5BAuthor%5D&cauthor=true&cauthor_uid=21041595) [Gavali S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gavali%20S%5BAuthor%5D&cauthor=true&cauthor_uid=21041595) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gavali%20S%5BAuthor%5D&cauthor=true&cauthor_uid=21041595) [Acosta M,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Acosta%20M%5BAuthor%5D&cauthor=true&cauthor_uid=21041595) et al.\nChildren hospitalized with 2009 novel influenza A(H1N1) in California. [Arch ](https://www.ncbi.nlm.nih.gov/pubmed/21041595) [Pediatr Adolesc Med](https://www.ncbi.nlm.nih.gov/pubmed/21041595) [2](https://www.ncbi.nlm.nih.gov/pubmed/21041595)010; 164(11): 1023-1031.\n105\nYen C, Louie J, Schechter R. Infants hospitalized in intensive care units with 2009 H1N1 influenza infection, California, 2009-2010. Pediatr Infect Dis J 2012; 31: e52\u2013e55.\n106\nDharan NJ, Sokolow LZ, Cheng PY, et al. Child, household, and caregiver characteristics associated with hospitalization for influenza among children 6-59 months of age: an emerging infections program study. Pediatr Infect Dis J 2014; 33(6): e141\u201350. 107\nGill PJ, Ashdown HF, Wang K, et al. Identification of children at risk of influenza related complications in primary and ambulatory care: a systematic review and meta-analysis. Lancet Respir Med 2015; 3(2): 139\u2013149.\n108\nGroothuis JR, Levin MJ, Lehr MV, et al. Immune response to split-product influenza vaccine in preterm and fullterm young children. Vaccine 1992; 10: 221\u2013225.\n109\nGroothuis JR, Lehr MV, Levin MJ. Safety and immunogenicity of a purified haemagglutinin antigen in very young high-risk children. Vaccine 1994; 12: 139\u2013141. 110\nSasaki Y, Kusuhara K, Saito M, et al. Serum immunoglobulin levels do not affect antibody responses to influenza HA vaccine in preterm infants. Vaccine 2006; 24: 2208\u20132212.\n111\nD\u2019Angio C, Heyne R, Duara S, et al. Immunogenicity of trivalent influenza vaccine in extremely-low-birth-weight, premature versus term infants. Pediatr infect Dis J 2011; 30: 570\u2013574.\n112\nD\u2019Angio CT, Wyman CP, Misra RS, et al. Plasma cell and serum antibody responses to influenza vaccine in preterm and full-term infants. Vaccine 2017; 35: 5163\u20135171.\n113\nShen S, Campitelli MA, Calzavara A, et al. Seasonal influenza vaccine effectiveness in pre- and full-term children aged 6\u201323 months over multiple seasons. Vaccine 2013; 31: 2974\u20132978.\n114\n[Blyth CC](https://www.ncbi.nlm.nih.gov/pubmed/?term=Blyth%20CC%5BAuthor%5D&cauthor=true&cauthor_uid=26646548) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Blyth%20CC%5BAuthor%5D&cauthor=true&cauthor_uid=26646548) [Jacoby P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Jacoby%20P%5BAuthor%5D&cauthor=true&cauthor_uid=26646548) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Jacoby%20P%5BAuthor%5D&cauthor=true&cauthor_uid=26646548) [Effler PV,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Effler%20PV%5BAuthor%5D&cauthor=true&cauthor_uid=26646548) et al.\nInfluenza vaccine effectiveness and uptake in children at risk of severe\ndisease. [Pediatr Infect Dis J](https://www.ncbi.nlm.nih.gov/pubmed/26646548) [2](https://www.ncbi.nlm.nih.gov/pubmed/26646548)016; 35(3): 309-315. 115 [Esposito S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Esposito%20S%5BAuthor%5D&cauthor=true&cauthor_uid=21464195) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Esposito%20S%5BAuthor%5D&cauthor=true&cauthor_uid=21464195) [Pugni L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pugni%20L%5BAuthor%5D&cauthor=true&cauthor_uid=21464195) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pugni%20L%5BAuthor%5D&cauthor=true&cauthor_uid=21464195) [Daleno C,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Daleno%20C%5BAuthor%5D&cauthor=true&cauthor_uid=21464195) et al.\nInfluenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to\n23 months. [Pediatrics.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Esposito+S%2C+Pugni+L%2C+Daleno+C%2C+Ronchi+A%2C+Valzano+A%2C+Serra+D%2C+et+al.+InfluenzaA%2FH1N1+MF59-adjuvanted+vaccine+in+preterm+and+term+children+aged+6+to+23months.+Pediatrics+2011%3B127(5)%3Ae1161%E2%80%938.) [2](https://www.ncbi.nlm.nih.gov/pubmed/?term=Esposito+S%2C+Pugni+L%2C+Daleno+C%2C+Ronchi+A%2C+Valzano+A%2C+Serra+D%2C+et+al.+InfluenzaA%2FH1N1+MF59-adjuvanted+vaccine+in+preterm+and+term+children+aged+6+to+23months.+Pediatrics+2011%3B127(5)%3Ae1161%E2%80%938.)011; 127(5): e1161-1168.\n116\nIreland. Health Service Executive. National Immunisation Office. Facts about flu. Disponible en:\n[https://www.hse.ie/eng/health/immunisation/pubinfo/flu](https://www.hse.ie/eng/health/immunisation/pubinfo/flu-vaccination/) [-](https://www.hse.ie/eng/health/immunisation/pubinfo/flu-vaccination/) [vaccination/](https://www.hse.ie/eng/health/immunisation/pubinfo/flu-vaccination/)\n117\nWHO\nvaccine-preventable diseases: monitoring system. 2019 global summary. (data as\nof 1-July-2019). Disponible en:\n[http://apps.who.int/immunization_monitoring/globalsummary/schedules](http://apps.who.int/immunization_monitoring/globalsummary/schedules)\n118\nCDC. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019\u201320 Influenza Season. MMWR Recomm Rep 2019; 68 (3): 1-21.\n119\nZhao L, Young K, Gemmill I on behalf of the National Advisory Committee on Immunization (NACI). Summary of the NACI Seasonal Influenza Vaccine Statement for 2019\u20132020. Can Commun Dis Rep 2019; 45(6): 149\u2013155,\n120\nMinistry of Health New Zealand. Immunisation Handbook 2017\n(2nd ed). Wellington: Ministry of Health. Disponible en:\n[https://www.health.govt.nz/publication/immunisation](https://www.health.govt.nz/publication/immunisation-handbook-2017) [-](https://www.health.govt.nz/publication/immunisation-handbook-2017) [handbook](https://www.health.govt.nz/publication/immunisation-handbook-2017) [-](https://www.health.govt.nz/publication/immunisation-handbook-2017) [2017](https://www.health.govt.nz/publication/immunisation-handbook-2017)\n121\nState of Israel. Ministry of Healh. Vaccines for Premature Babies.\n[https://www.health.gov.il/English/Topics/Pregnancy/Vaccination_of_infants/Pages/vaccine_premature_baby.aspx](https://www.health.gov.il/English/Topics/Pregnancy/Vaccination_of_infants/Pages/vaccine_premature_baby.aspx)\n122\n[Walter EB](https://www.ncbi.nlm.nih.gov/pubmed/?term=Walter%20EB%5BAuthor%5D&cauthor=true&cauthor_uid=19935270) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Walter%20EB%5BAuthor%5D&cauthor=true&cauthor_uid=19935270) [Englund JA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Englund%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=19935270) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Englund%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=19935270) [Blatter M,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Blatter%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19935270) et al.\nTrivalent inactivated influenza virus vaccine given to two-month-old children:\nan off-season pilot study [. Pediatr Infect Dis J](https://www.ncbi.nlm.nih.gov/pubmed/?term=PIDJ+2009%3B28%3A1099-1104) [2](https://www.ncbi.nlm.nih.gov/pubmed/?term=PIDJ+2009%3B28%3A1099-1104)009; 28: 1099-1104.\n123\n[Englund JA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Englund%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=19934787) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Englund%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=19934787) [Walter E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Walter%20E%5BAuthor%5D&cauthor=true&cauthor_uid=19934787) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Walter%20E%5BAuthor%5D&cauthor=true&cauthor_uid=19934787) [Black S,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Black%20S%5BAuthor%5D&cauthor=true&cauthor_uid=19934787) et al.\nSafety and immunogenicity of trivalent inactivated influenza vaccine in\ninfants: a randomized double-blind placebo-controlled study [. Pediatr Infect Dis J](https://www.ncbi.nlm.nih.gov/pubmed/19934787)\n124\n[Halasa NB](https://www.ncbi.nlm.nih.gov/pubmed/?term=Halasa%20NB%5BAuthor%5D&cauthor=true&cauthor_uid=18444800) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Halasa%20NB%5BAuthor%5D&cauthor=true&cauthor_uid=18444800) [Gerber MA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gerber%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=18444800) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gerber%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=18444800) [Chen Q,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Chen%20Q%5BAuthor%5D&cauthor=true&cauthor_uid=18444800) et al.\nSafety and immunogenicity of trivalent inactivated influenza vaccine in\ninfants. [J Infect Dis](https://www.ncbi.nlm.nih.gov/pubmed/18444800) [Moro PL](https://www.ncbi.nlm.nih.gov/pubmed/?term=Moro%20PL%5BAuthor%5D&cauthor=true&cauthor_uid=20965490) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Moro%20PL%5BAuthor%5D&cauthor=true&cauthor_uid=20965490) [Brode](https://www.ncbi.nlm.nih.gov/pubmed/?term=Broder%20K%5BAuthor%5D&cauthor=true&cauthor_uid=20965490) [r](https://www.ncbi.nlm.nih.gov/pubmed/?term=Broder%20K%5BAuthor%5D&cauthor=true&cauthor_uid=20965490) [K](https://www.ncbi.nlm.nih.gov/pubmed/?term=Broder%20K%5BAuthor%5D&cauthor=true&cauthor_uid=20965490) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Broder%20K%5BAuthor%5D&cauthor=true&cauthor_uid=20965490) [Zheteyev](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zheteyeva%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=20965490) [a](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zheteyeva%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=20965490) [Y,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zheteyeva%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=20965490) et al. Adverse events in\npregnant women following administration of trivalent inactivated influenza\nvaccine and live attenuated influenza vaccine in the Vaccine Adverse Event\nReporting System, 1990-2009. Am J Obstet Gynecol 2011; 204: 146.e1-7.\n126\nNunes MC, Madhi SA.\nReview on the effects of influenza vaccination during pregnancy on preterm\nbirths.\n[Hum ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685674/) [Vaccin Immunother](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685674/)\n127\nFell DB, Azziz-Baumgartner E, Baker MG, et al. Influenza epidemiology and immunization during pregnancy: final report of a World Health Organization working group. Vaccine 2017; 35: 5738\u20135750.\n128\n[M\u00f8lgaard](https://www.ncbi.nlm.nih.gov/pubmed/?term=M%C3%B8lgaard-Nielsen%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31259452) [-](https://www.ncbi.nlm.nih.gov/pubmed/?term=M%C3%B8lgaard-Nielsen%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31259452) [Nielsen D](https://www.ncbi.nlm.nih.gov/pubmed/?term=M%C3%B8lgaard-Nielsen%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31259452) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=M%C3%B8lgaard-Nielsen%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31259452) [Fischer TK](https://www.ncbi.nlm.nih.gov/pubmed/?term=Fischer%20TK%5BAuthor%5D&cauthor=true&cauthor_uid=31259452) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Fischer%20TK%5BAuthor%5D&cauthor=true&cauthor_uid=31259452) [Krause TG,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Krause%20TG%5BAuthor%5D&cauthor=true&cauthor_uid=31259452) et al.\nEffectiveness of maternal immunization with trivalent inactivated influenza\nvaccine in pregnant women and their infants. [J Intern Med](https://www.ncbi.nlm.nih.gov/pubmed/31259452) [2](https://www.ncbi.nlm.nih.gov/pubmed/31259452)019; 286(4): 469-480.\n129\nMazagatos C, Godoy P, Mu\u00f1oz Almagro C, et al. Efectividad de la vacuna antigripal en embarazadas para prevenir gripe grave en ni\u00f1os menores de seis meses (Abstract 621, p\u00e1g 101). Espa\u00f1a, 2017-2019. Gac Sanit 2019; 33(Espec Congr): 6-125. 130\nSlack MH, Schapira D. Severe apnoeas following immunization in premature infants. Arch Dis Child Fetal Neonatal Ed 1999; 81: F67-68.\n131\nPfister RE, Aeschbach V, Niksic-Stuber V, et al. Safety of DTaP-based combined immunization in very low-birthweight premature infants: frequent but mostly benign cardiorespiratory events. J Pediatr 2004; 145(1): 58\u201366.\n132\nPourcyrous M, Korones SB, Crouse D, et al. Interleukin-6, C reactive protein, and abnormal cardiorespiratory responses to immunization in preterm infants. Pediatrics1998, 101: pe3.\n133\n[Lee J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20J%5BAuthor%5D&cauthor=true&cauthor_uid=16784533) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20J%5BAuthor%5D&cauthor=true&cauthor_uid=16784533) [Robinson JL](https://www.ncbi.nlm.nih.gov/pubmed/?term=Robinson%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=16784533) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Robinson%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=16784533) [Spady DW.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Spady%20DW%5BAuthor%5D&cauthor=true&cauthor_uid=16784533) Frequency\nof apnea, bradycardia, and desaturations following first\ndiphtheriatetanus-pertussis-inactivated polio-Haemophilus influenzae type B immunization in hospitalized preterm\ninfants. [BMC Pediatr](https://www.ncbi.nlm.nih.gov/pubmed/16784533) [2](https://www.ncbi.nlm.nih.gov/pubmed/16784533)006; 6: 20.\n134\n[Carbone T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Carbone%20T%5BAuthor%5D&cauthor=true&cauthor_uid=18450851) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Carbone%20T%5BAuthor%5D&cauthor=true&cauthor_uid=18450851) [McEntire B](https://www.ncbi.nlm.nih.gov/pubmed/?term=McEntire%20B%5BAuthor%5D&cauthor=true&cauthor_uid=18450851) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=McEntire%20B%5BAuthor%5D&cauthor=true&cauthor_uid=18450851) [Kissin D,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kissin%20D%5BAuthor%5D&cauthor=true&cauthor_uid=18450851) et al.\nAbsence of an increase in cardiorespiratory events after\ndiphtheria-tetanusacellular pertussis immunization in preterm infants: a\nrandomized, multicenter study. [Pediatrics](https://www.ncbi.nlm.nih.gov/pubmed/18450851)\n135\nHealy CM. Immunization strategies to protect preterm infants. NeoReviews 2010; 11(8): e409-e418.\n136\n[Klein NP](https://www.ncbi.nlm.nih.gov/pubmed/?term=Klein%20NP%5BAuthor%5D&cauthor=true&cauthor_uid=18310193) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Klein%20NP%5BAuthor%5D&cauthor=true&cauthor_uid=18310193) [Massolo ML](https://www.ncbi.nlm.nih.gov/pubmed/?term=Massolo%20ML%5BAuthor%5D&cauthor=true&cauthor_uid=18310193) [,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Massolo%20ML%5BAuthor%5D&cauthor=true&cauthor_uid=18310193) [Greene J,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Greene%20J%5BAuthor%5D&cauthor=true&cauthor_uid=18310193) et al.\nRisk factors for developing apnea after immunization in the neonatal intensive\ncare unit. [Pediatrics](https://www.ncbi.nlm.nih.gov/pubmed/?term=Greene+J%2C+Dekker+CL%2C+Black+S%2C+Escobar+GJ)\nS\u00edguenos en redes sociales", "language": null, "image": "https://diariofarma.com/wp-content/uploads/2016/01/Nueva-SocialCard-diariofarma3.png", "pagetype": "article", "links": ["#", "https://diariofarma.com/", "https://diariofarma.com/politica", "https://diariofarma.com/profesion", "https://diariofarma.com/gestion", "https://diariofarma.com/terapeutica", "https://diariofarma.com/opinion", "https://diariofarma.com/farmacia-asistencial-2", "https://diariofarma.com/farmacia-hospitalaria-3-2-2", "https://diariofarma.com/documentacion", "https://diariofarma.com/busqueda", "https://diariofarma.com/newsletter-2", "https://www.addtoany.com/add_to/facebook?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/twitter?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/whatsapp?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/linkedin?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/meneame?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/email?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/printfriendly?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/flipboard?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/share", "https://diariofarma.com/tag/agencia-europea-de-medicamentos-ema", "https://diariofarma.com/tag/andalucia", "https://diariofarma.com/tag/asociacion-espanola-de-pediatria-aep", "https://diariofarma.com/tag/cataluna", "https://diariofarma.com/tag/ceuta", "https://diariofarma.com/tag/cirugia", "https://diariofarma.com/tag/consejeria-de-sanidad-de-galicia", "https://diariofarma.com/tag/consejo-interterritorial-del-sns-cisns", "https://diariofarma.com/tag/difteria", "https://diariofarma.com/tag/direccion-general-de-salud-publica", "https://diariofarma.com/tag/enfermeria", "https://diariofarma.com/tag/estados-unidos", "https://diariofarma.com/tag/galicia", "https://diariofarma.com/tag/gripe", "https://diariofarma.com/tag/hepatitis-a", "https://diariofarma.com/tag/hepatitis-b", "https://diariofarma.com/tag/inmunologia", "https://diariofarma.com/tag/innovacion", "https://diariofarma.com/tag/instituto-nacional-de-estadistica-ine", "https://diariofarma.com/tag/islas-baleares", "https://diariofarma.com/tag/medicina-preventiva", "https://diariofarma.com/tag/melilla", "https://diariofarma.com/tag/microbiologia", "https://diariofarma.com/tag/ministerio-de-sanidad", "https://diariofarma.com/tag/navarra", "https://diariofarma.com/tag/neumologia", "https://diariofarma.com/tag/pais-vasco", "https://diariofarma.com/tag/pediatria", "https://diariofarma.com/tag/prevencion", "https://diariofarma.com/tag/region-de-murcia", "https://diariofarma.com/tag/rotavirus", "https://diariofarma.com/tag/salud-publica", "https://diariofarma.com/tag/seguridad", "https://diariofarma.com/tag/sistema-nacional-de-salud-sns", "https://diariofarma.com/tag/vacunas", "https://www.addtoany.com/add_to/facebook?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/twitter?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/whatsapp?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/linkedin?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/meneame?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/email?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/printfriendly?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/flipboard?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/share", "https://diariofarma.com/2023/09/25/9-de-cada-10-centros-no-analiza-las-superficies-donde-se-preparan-farmacos-peligrosos-segun-enfermeria", "https://diariofarma.com/2023/09/24/bidafarma-reune-a-mas-de-1-000-profesionales-de-la-farmacia-en-exposervicios-sevilla", "https://diariofarma.com/2023/09/24/el-cof-de-alava-celebra-su-125-aniversario-reforzando-su-compromiso-con-la-sociedad", "https://diariofarma.com/2023/09/24/la-farmacia-reivindica-su-papel-como-fortalecedor-del-sistema", "https://diariofarma.com/2023/09/24/minones-se-compromete-a-desarrollar-el-programa-de-farmacia-rural-antes-de-final-de-ano", null, null, "#_Toc50994", "#_Toc50995", "#_Toc50996", "#_Toc50997", "#_Toc50998", "#_Toc50999", "#_Toc51000", "#_Toc51001", "#_Toc51002", "#_Toc51003", "#_Toc51004", "#_Toc51005", "#_Toc51006", "#_Toc51007", null, null, null, null, null, null, null, null, null, null, null, null, "http://www.ine.es/", "http://www.ine.es/", "http://www.ine.es/", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Baxter%20D%5BAuthor%5D&cauthor=true&cauthor_uid=20519937", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Baxter%20D%5BAuthor%5D&cauthor=true&cauthor_uid=20519937", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Baxter%20D%5BAuthor%5D&cauthor=true&cauthor_uid=20519937", "https://www.ncbi.nlm.nih.gov/pubmed/20519937", "https://www.ncbi.nlm.nih.gov/pubmed/20519937", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bednarek%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30033997", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bednarek%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30033997", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bednarek%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30033997", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bednarek%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30033997", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bartkowiak-Emeryk%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30033997", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bartkowiak-Emeryk%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30033997", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bartkowiak-Emeryk%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30033997", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bartkowiak-Emeryk%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30033997", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Klepacz%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30033997", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Klepacz%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30033997", "https://www.ncbi.nlm.nih.gov/pubmed/30033997", "https://www.ncbi.nlm.nih.gov/pubmed/30033997", "http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Revision_CalendarioVacunacion.pdf", "http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Revision_CalendarioVacunacion.pdf", "http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Revision_CalendarioVacunacion.pdf", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Hofstetter%20AM%5BAuthor%5D&cauthor=true&cauthor_uid=31391213", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Hofstetter%20AM%5BAuthor%5D&cauthor=true&cauthor_uid=31391213", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Hofstetter%20AM%5BAuthor%5D&cauthor=true&cauthor_uid=31391213", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Jacobson%20EN%5BAuthor%5D&cauthor=true&cauthor_uid=31391213", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Jacobson%20EN%5BAuthor%5D&cauthor=true&cauthor_uid=31391213", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Jacobson%20EN%5BAuthor%5D&cauthor=true&cauthor_uid=31391213", "https://www.ncbi.nlm.nih.gov/pubmed/?term=deHart%20MP%5BAuthor%5D&cauthor=true&cauthor_uid=31391213", "https://www.ncbi.nlm.nih.gov/pubmed/?term=deHart%20MP%5BAuthor%5D&cauthor=true&cauthor_uid=31391213", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Early+Childhood+Vaccination+Status+of+Preterm+Infants", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Early+Childhood+Vaccination+Status+of+Preterm+Infants", "https://www.infovac.ch/docs/public/fs/plan-de-vaccination-2019.pdf", "https://www.infovac.ch/docs/public/fs/plan-de-vaccination-2019.pdf", "https://www.infovac.ch/docs/public/fs/plan-de-vaccination-2019.pdf", "https://www.infovac.ch/docs/public/fs/plan-de-vaccination-2019.pdf", "https://www.infovac.ch/docs/public/fs/plan-de-vaccination-2019.pdf", "https://www.infovac.ch/docs/public/fs/plan-de-vaccination-2019.pdf", "https://www.infovac.ch/docs/public/fs/plan-de-vaccination-2019.pdf", "https://www.infovac.ch/docs/public/fs/plan-de-vaccination-2019.pdf", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-april-2019", "https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women", "https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women", "https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women", "https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women", "https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women", "https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women", "https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women", "https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women", "https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women", "https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women", "https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women", "https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women", "https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women", "https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women", "https://www.gov.uk/government/publications/vaccination-against-pertussis-whooping-cough-for-pregnant-women", "https://app.box.com/s/iddfb4ppwkmtjusir2tc/file/492419147748", "https://app.box.com/s/iddfb4ppwkmtjusir2tc/file/492419147748", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Tiwari%20T%5BAuthor%5D&cauthor=true&cauthor_uid=29702631", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Tiwari%20T%5BAuthor%5D&cauthor=true&cauthor_uid=29702631", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Moro%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29702631", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Moro%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29702631", "http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/difteria_tetano_tosferina.htm", "http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/difteria_tetano_tosferina.htm", "http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/difteria_tetano_tosferina.htm", "http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/VacGruposRiesgo/Vac_GruposRiesgo_todasEdades.htm", "http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/VacGruposRiesgo/Vac_GruposRiesgo_todasEdades.htm", "http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/VacGruposRiesgo/Vac_GruposRiesgo_todasEdades.htm", "https://apps.who.int/iris/bitstream/handle/10665/77755/9789241504751_eng.pdf;jsessionid=272BC1A4661C4301E04A0AD63466C6CA?sequence=1", "https://apps.who.int/iris/bitstream/handle/10665/77755/9789241504751_eng.pdf;jsessionid=272BC1A4661C4301E04A0AD63466C6CA?sequence=1", "https://apps.who.int/iris/bitstream/handle/10665/77755/9789241504751_eng.pdf;jsessionid=272BC1A4661C4301E04A0AD63466C6CA?sequence=1", "https://www.ncbi.nlm.nih.gov/pubmed/28685564", "https://www.ncbi.nlm.nih.gov/pubmed/28685564", "https://www.ncbi.nlm.nih.gov/pubmed/28685564", "https://www.ncbi.nlm.nih.gov/pubmed/28685564", "https://www.ncbi.nlm.nih.gov/pubmed/28685564", "http://vacunasaep.org/documentos/manual/cap-29", "http://vacunasaep.org/documentos/manual/cap-29", "http://vacunasaep.org/documentos/manual/cap-29", "http://vacunasaep.org/documentos/manual/cap-29", "http://vacunasaep.org/documentos/manual/cap-29", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Tr%C3%BCck%20J%5BAuthor%5D&cauthor=true&cauthor_uid=20851537", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Tr%C3%BCck%20J%5BAuthor%5D&cauthor=true&cauthor_uid=20851537", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Tr%C3%BCck%20J%5BAuthor%5D&cauthor=true&cauthor_uid=20851537", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Pollard%20AJ%5BAuthor%5D&cauthor=true&cauthor_uid=20851537", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Pollard%20AJ%5BAuthor%5D&cauthor=true&cauthor_uid=20851537", "https://www.ncbi.nlm.nih.gov/pubmed/?term=preterm+infants+and+invasive+disease%2C+meningococcal%2C+haemophilus+influenzae", "https://www.ncbi.nlm.nih.gov/pubmed/?term=preterm+infants+and+invasive+disease%2C+meningococcal%2C+haemophilus+influenzae", "https://www.ncbi.nlm.nih.gov/pubmed/?term=preterm+infants+and+invasive+disease%2C+meningococcal%2C+haemophilus+influenzae", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Okike%20IO%5BAuthor%5D&cauthor=true&cauthor_uid=24997051", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Okike%20IO%5BAuthor%5D&cauthor=true&cauthor_uid=24997051", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Okike%20IO%5BAuthor%5D&cauthor=true&cauthor_uid=24997051", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Johnson%20AP%5BAuthor%5D&cauthor=true&cauthor_uid=24997051", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Johnson%20AP%5BAuthor%5D&cauthor=true&cauthor_uid=24997051", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Johnson%20AP%5BAuthor%5D&cauthor=true&cauthor_uid=24997051", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Henderson%20KL%5BAuthor%5D&cauthor=true&cauthor_uid=24997051", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Henderson%20KL%5BAuthor%5D&cauthor=true&cauthor_uid=24997051", "https://www.ncbi.nlm.nih.gov/pubmed/24997051", "https://www.ncbi.nlm.nih.gov/pubmed/24997051", "https://www.ncbi.nlm.nih.gov/pubmed/24997051", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Gagneur%20A%5BAuthor%5D&cauthor=true&cauthor_uid=26291883", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Gagneur%20A%5BAuthor%5D&cauthor=true&cauthor_uid=26291883", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Gagneur%20A%5BAuthor%5D&cauthor=true&cauthor_uid=26291883", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Pinquier%20D%5BAuthor%5D&cauthor=true&cauthor_uid=26291883", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Pinquier%20D%5BAuthor%5D&cauthor=true&cauthor_uid=26291883", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Pinquier%20D%5BAuthor%5D&cauthor=true&cauthor_uid=26291883", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Quach%20C%5BAuthor%5D&cauthor=true&cauthor_uid=26291883", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Quach%20C%5BAuthor%5D&cauthor=true&cauthor_uid=26291883", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Quach%20C%5BAuthor%5D&cauthor=true&cauthor_uid=26291883", "https://www.ncbi.nlm.nih.gov/pubmed/26291883", "https://www.ncbi.nlm.nih.gov/pubmed/26291883", "https://www.ncbi.nlm.nih.gov/pubmed", "https://www.ncbi.nlm.nih.gov/pubmed", "https://www.ncbi.nlm.nih.gov/pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Kent%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30281069", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Kent%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30281069", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Makwana%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30281069", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Makwana%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30281069", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Makwana%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30281069", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Sheppard%20CL%5BAuthor%5D&cauthor=true&cauthor_uid=30281069", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Sheppard%20CL%5BAuthor%5D&cauthor=true&cauthor_uid=30281069", "https://www.ncbi.nlm.nih.gov/pubmed/30281069", "https://www.ncbi.nlm.nih.gov/pubmed/30281069", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Yildirim%20I%5BAuthor%5D&cauthor=true&cauthor_uid=30281070", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Yildirim%20I%5BAuthor%5D&cauthor=true&cauthor_uid=30281070", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Yildirim%20I%5BAuthor%5D&cauthor=true&cauthor_uid=30281070", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Pelton%20SI%5BAuthor%5D&cauthor=true&cauthor_uid=30281070", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Pelton%20SI%5BAuthor%5D&cauthor=true&cauthor_uid=30281070", "https://www.ncbi.nlm.nih.gov/pubmed/30281070", "https://www.ncbi.nlm.nih.gov/pubmed/30281070", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Martin%C3%B3n-Torres%20F%5BAuthor%5D&cauthor=true&cauthor_uid=27902652", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Martin%C3%B3n-Torres%20F%5BAuthor%5D&cauthor=true&cauthor_uid=27902652", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Martin%C3%B3n-Torres%20F%5BAuthor%5D&cauthor=true&cauthor_uid=27902652", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Martin%C3%B3n-Torres%20F%5BAuthor%5D&cauthor=true&cauthor_uid=27902652", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Martin%C3%B3n-Torres%20F%5BAuthor%5D&cauthor=true&cauthor_uid=27902652", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Wysocki%20J%5BAuthor%5D&cauthor=true&cauthor_uid=27902652", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Wysocki%20J%5BAuthor%5D&cauthor=true&cauthor_uid=27902652", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Center%20KJ%5BAuthor%5D&cauthor=true&cauthor_uid=27902652", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Center%20KJ%5BAuthor%5D&cauthor=true&cauthor_uid=27902652", "https://www.ncbi.nlm.nih.gov/pubmed/27902652", "https://www.ncbi.nlm.nih.gov/pubmed/27902652", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Ome%C3%B1aca%20F%5BAuthor%5D&cauthor=true&cauthor_uid=29336924", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Ome%C3%B1aca%20F%5BAuthor%5D&cauthor=true&cauthor_uid=29336924", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Ome%C3%B1aca%20F%5BAuthor%5D&cauthor=true&cauthor_uid=29336924", "https://www.ncbi.nlm.nih.gov/pubmed/?term=V%C3%A1zquez%20L%5BAuthor%5D&cauthor=true&cauthor_uid=29336924", "https://www.ncbi.nlm.nih.gov/pubmed/?term=V%C3%A1zquez%20L%5BAuthor%5D&cauthor=true&cauthor_uid=29336924", "https://www.ncbi.nlm.nih.gov/pubmed/?term=V%C3%A1zquez%20L%5BAuthor%5D&cauthor=true&cauthor_uid=29336924", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Garcia-Corbeira%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29336924", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Garcia-Corbeira%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29336924", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Garcia-Corbeira%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29336924", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Garcia-Corbeira%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29336924", "https://www.ncbi.nlm.nih.gov/pubmed/?term=omenaca+immunization+preterm+infants+with+GSK+2018", "https://www.ncbi.nlm.nih.gov/pubmed/?term=omenaca+immunization+preterm+infants+with+GSK+2018", "https://atlas.ecdc.europa.eu/public/index.aspx", "https://atlas.ecdc.europa.eu/public/index.aspx", "https://atlas.ecdc.europa.eu/public/index.aspx", "http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Recomendaciones_Vacunacion_Meningococo.pdf", "http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Recomendaciones_Vacunacion_Meningococo.pdf", "http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Recomendaciones_Vacunacion_Meningococo.pdf", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Wili%C5%84ska%20M%5BAuthor%5D&cauthor=true&cauthor_uid=28216484", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Wili%C5%84ska%20M%5BAuthor%5D&cauthor=true&cauthor_uid=28216484", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Wili%C5%84ska%20M%5BAuthor%5D&cauthor=true&cauthor_uid=28216484", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Warakomska%20M%5BAuthor%5D&cauthor=true&cauthor_uid=28216484", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Warakomska%20M%5BAuthor%5D&cauthor=true&cauthor_uid=28216484", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Warakomska%20M%5BAuthor%5D&cauthor=true&cauthor_uid=28216484", "https://www.ncbi.nlm.nih.gov/pubmed/?term=G%C5%82uszczak-Idziakowska%20E%5BAuthor%5D&cauthor=true&cauthor_uid=28216484", "https://www.ncbi.nlm.nih.gov/pubmed/?term=G%C5%82uszczak-Idziakowska%20E%5BAuthor%5D&cauthor=true&cauthor_uid=28216484", "https://www.ncbi.nlm.nih.gov/pubmed/?term=G%C5%82uszczak-Idziakowska%20E%5BAuthor%5D&cauthor=true&cauthor_uid=28216484", "https://www.ncbi.nlm.nih.gov/pubmed/?term=G%C5%82uszczak-Idziakowska%20E%5BAuthor%5D&cauthor=true&cauthor_uid=28216484", "https://www.ncbi.nlm.nih.gov/pubmed/28216484", "https://www.ncbi.nlm.nih.gov/pubmed/28216484", "https://vaccine-schedule.ecdc.europa.eu/", "https://vaccine-schedule.ecdc.europa.eu/", "https://vaccine-schedule.ecdc.europa.eu/", "https://solidarites-sante.gouv.fr/IMG/pdf/calendrier_vaccinal_maj_17avril2019.pdf", "https://solidarites-sante.gouv.fr/IMG/pdf/calendrier_vaccinal_maj_17avril2019.pdf", "https://solidarites-sante.gouv.fr/IMG/pdf/calendrier_vaccinal_maj_17avril2019.pdf", "https://solidarites-sante.gouv.fr/IMG/pdf/calendrier_vaccinal_maj_17avril2019.pdf", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-preterm-infants", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-5-immunization-infants-born-prematurely.html", "https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/566853/Green_Book_Chapter7.pdf", "https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/566853/Green_Book_Chapter7.pdf", "https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/566853/Green_Book_Chapter7.pdf", "https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/immunisationguidelines.html", "https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/immunisationguidelines.html", "https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme", "https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme", "https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme", "https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme", "https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme", "https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme", "https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme", "https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme", "https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme", "https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://thl.fi/en/web/vaccination/national-vaccination-programme/vaccination-programme-for-children-and-adolescents", "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf", "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf", "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf", "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf", "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf", "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf", "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf", "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf", "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf", "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf", "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf", "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf", "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf", "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf", "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/vaksine/vaccination-of-preterm-infants-against-pertussis-and-pneumococci_web.pdf", "https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf", "https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf", "https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf", "https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf", "https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf", "https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf", "https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf", "https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf", "https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf", "https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf", "https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf", "https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf", "https://www.health.govt.nz/system/files/documents/publications/immshandbook-4-immunisation-special-groups-mar18-v3.pdf", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Goldblatt%20D%5BAuthor%5D&cauthor=true&cauthor_uid=29174323", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Goldblatt%20D%5BAuthor%5D&cauthor=true&cauthor_uid=29174323", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Goldblatt%20D%5BAuthor%5D&cauthor=true&cauthor_uid=29174323", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Southern%20J%5BAuthor%5D&cauthor=true&cauthor_uid=29174323", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Southern%20J%5BAuthor%5D&cauthor=true&cauthor_uid=29174323", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Southern%20J%5BAuthor%5D&cauthor=true&cauthor_uid=29174323", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Andrews%20NJ%5BAuthor%5D&cauthor=true&cauthor_uid=29174323", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Andrews%20NJ%5BAuthor%5D&cauthor=true&cauthor_uid=29174323", "https://www.ncbi.nlm.nih.gov/pubmed/29174323", "https://www.ncbi.nlm.nih.gov/pubmed/29174323", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Carter%20ED%5BAuthor%5D&cauthor=true&cauthor_uid=31375441", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Carter%20ED%5BAuthor%5D&cauthor=true&cauthor_uid=31375441", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Carter%20ED%5BAuthor%5D&cauthor=true&cauthor_uid=31375441", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Carter%20ED%5BAuthor%5D&cauthor=true&cauthor_uid=31375441", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Carter%20ED%5BAuthor%5D&cauthor=true&cauthor_uid=31375441", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Tam%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=31375441", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Tam%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=31375441", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Tam%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=31375441", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Walker%20N%5BAuthor%5D&cauthor=true&cauthor_uid=31375441", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Walker%20N%5BAuthor%5D&cauthor=true&cauthor_uid=31375441", "https://www.ncbi.nlm.nih.gov/pubmed?term=2019%5Bpdat%5D+AND+carter%5Bauthor%5D+AND+Impact+of+vaccination+delay+on+deaths+averted+by+pneumococcal+conjugate+vaccine%3A+Modeled+effects+in+8+country+scenarios&TransSchema=title&cmd=detailssearch", "https://www.ncbi.nlm.nih.gov/pubmed?term=2019%5Bpdat%5D+AND+carter%5Bauthor%5D+AND+Impact+of+vaccination+delay+on+deaths+averted+by+pneumococcal+conjugate+vaccine%3A+Modeled+effects+in+8+country+scenarios&TransSchema=title&cmd=detailssearch", "http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/coberturas.htm", "http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/coberturas.htm", "https://cima.aemps.es/cima/dochtml/ft/06348001/FT_06348001.html", "https://cima.aemps.es/cima/dochtml/ft/06348001/FT_06348001.html", "https://cima.aemps.es/cima/dochtml/ft/06348001/FT_06348001.html", "https://cima.aemps.es/cima/dochtml/ft/05330009/FT_05330009.html", "https://cima.aemps.es/cima/dochtml/ft/05330009/FT_05330009.html", "https://cima.aemps.es/cima/dochtml/ft/05330009/FT_05330009.html", "https://www.ncbi.nlm.nih.gov/pubmed/?term=van%20der%20Woude%20CJ%5BAuthor%5D&cauthor=true&cauthor_uid=25602023", "https://www.ncbi.nlm.nih.gov/pubmed/?term=van%20der%20Woude%20CJ%5BAuthor%5D&cauthor=true&cauthor_uid=25602023", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Ardizzone%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25602023", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Ardizzone%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25602023", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Ardizzone%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25602023", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bengtson%20MB%5BAuthor%5D&cauthor=true&cauthor_uid=25602023", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bengtson%20MB%5BAuthor%5D&cauthor=true&cauthor_uid=25602023", "https://www.ncbi.nlm.nih.gov/pubmed/?term=J+Crohns+colitis+2014%3B9%3A107-124", "https://www.ncbi.nlm.nih.gov/pubmed/?term=J+Crohns+colitis+2014%3B9%3A107-124", "https://www.ncbi.nlm.nih.gov/pubmed/?term=J+Crohns+colitis+2014%3B9%3A107-124", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Desalermos%20AP%5BAuthor%5D&cauthor=true&cauthor_uid=25160668", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Desalermos%20AP%5BAuthor%5D&cauthor=true&cauthor_uid=25160668", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Desalermos%20AP%5BAuthor%5D&cauthor=true&cauthor_uid=25160668", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Farraye%20FA%5BAuthor%5D&cauthor=true&cauthor_uid=25160668", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Farraye%20FA%5BAuthor%5D&cauthor=true&cauthor_uid=25160668", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Farraye%20FA%5BAuthor%5D&cauthor=true&cauthor_uid=25160668", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Wasan%20SK%5BAuthor%5D&cauthor=true&cauthor_uid=25160668", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Wasan%20SK%5BAuthor%5D&cauthor=true&cauthor_uid=25160668", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Wasan%20SK%5BAuthor%5D&cauthor=true&cauthor_uid=25160668", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Expert+rev+gastroenterol+hepatol+2014%3B9%3A91-102", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Expert+rev+gastroenterol+hepatol+2014%3B9%3A91-102", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Expert+rev+gastroenterol+hepatol+2014%3B9%3A91-102", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Expert+rev+gastroenterol+hepatol+2014%3B9%3A91-102", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Long%20MD%5BAuthor%5D&cauthor=true&cauthor_uid=25966839", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Long%20MD%5BAuthor%5D&cauthor=true&cauthor_uid=25966839", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Long%20MD%5BAuthor%5D&cauthor=true&cauthor_uid=25966839", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Gulati%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25966839", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Gulati%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25966839", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Gulati%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25966839", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Wohl%20D%5BAuthor%5D&cauthor=true&cauthor_uid=25966839", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Wohl%20D%5BAuthor%5D&cauthor=true&cauthor_uid=25966839", "https://www.ncbi.nlm.nih.gov/pubmed/?term=inflamm+bowel+dis+2015%3B21%3A1993", "https://www.ncbi.nlm.nih.gov/pubmed/?term=inflamm+bowel+dis+2015%3B21%3A1993", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Nguyen%20GC%5BAuthor%5D&cauthor=true&cauthor_uid=26688268", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Nguyen%20GC%5BAuthor%5D&cauthor=true&cauthor_uid=26688268", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Nguyen%20GC%5BAuthor%5D&cauthor=true&cauthor_uid=26688268", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Seow%20CH%5BAuthor%5D&cauthor=true&cauthor_uid=26688268", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Seow%20CH%5BAuthor%5D&cauthor=true&cauthor_uid=26688268", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Seow%20CH%5BAuthor%5D&cauthor=true&cauthor_uid=26688268", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Maxwell%20C%5BAuthor%5D&cauthor=true&cauthor_uid=26688268", "https://www.ncbi.nlm.nih.gov/pubmed/?term=gastroenterology+2016%3B150%3A734", "https://www.ncbi.nlm.nih.gov/pubmed/?term=gastroenterology+2016%3B150%3A734", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Dinelli%20MIS%5BAuthor%5D&cauthor=true&cauthor_uid=29890028", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Dinelli%20MIS%5BAuthor%5D&cauthor=true&cauthor_uid=29890028", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Dinelli%20MIS%5BAuthor%5D&cauthor=true&cauthor_uid=29890028", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Dos%20Santos%20AMN%5BAuthor%5D&cauthor=true&cauthor_uid=29890028", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Dos%20Santos%20AMN%5BAuthor%5D&cauthor=true&cauthor_uid=29890028", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Dos%20Santos%20AMN%5BAuthor%5D&cauthor=true&cauthor_uid=29890028", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Weckx%20LY%5BAuthor%5D&cauthor=true&cauthor_uid=29890028", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Weckx%20LY%5BAuthor%5D&cauthor=true&cauthor_uid=29890028", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Weckx%20LY%5BAuthor%5D&cauthor=true&cauthor_uid=29890028", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Weckx%20LY%5BAuthor%5D&cauthor=true&cauthor_uid=29890028", "https://www.ncbi.nlm.nih.gov/pubmed/29890028", "https://www.ncbi.nlm.nih.gov/pubmed/29890028", "https://www.ncbi.nlm.nih.gov/pubmed/29890028", "https://www.ncbi.nlm.nih.gov/pubmed/29890028", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Izurieta%20HS%5BAuthor%5D&cauthor=true&cauthor_uid=10648764", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Izurieta%20HS%5BAuthor%5D&cauthor=true&cauthor_uid=10648764", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Izurieta%20HS%5BAuthor%5D&cauthor=true&cauthor_uid=10648764", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Thompson%20WW%5BAuthor%5D&cauthor=true&cauthor_uid=10648764", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Thompson%20WW%5BAuthor%5D&cauthor=true&cauthor_uid=10648764", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Thompson%20WW%5BAuthor%5D&cauthor=true&cauthor_uid=10648764", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Kramarz%20P%5BAuthor%5D&cauthor=true&cauthor_uid=10648764", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Kramarz%20P%5BAuthor%5D&cauthor=true&cauthor_uid=10648764", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Kramarz%20P%5BAuthor%5D&cauthor=true&cauthor_uid=10648764", "https://www.ncbi.nlm.nih.gov/pubmed/10648764", "https://www.ncbi.nlm.nih.gov/pubmed/10648764", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Louie%20JK%5BAuthor%5D&cauthor=true&cauthor_uid=21041595", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Louie%20JK%5BAuthor%5D&cauthor=true&cauthor_uid=21041595", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Louie%20JK%5BAuthor%5D&cauthor=true&cauthor_uid=21041595", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Gavali%20S%5BAuthor%5D&cauthor=true&cauthor_uid=21041595", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Gavali%20S%5BAuthor%5D&cauthor=true&cauthor_uid=21041595", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Gavali%20S%5BAuthor%5D&cauthor=true&cauthor_uid=21041595", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Acosta%20M%5BAuthor%5D&cauthor=true&cauthor_uid=21041595", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Acosta%20M%5BAuthor%5D&cauthor=true&cauthor_uid=21041595", "https://www.ncbi.nlm.nih.gov/pubmed/21041595", "https://www.ncbi.nlm.nih.gov/pubmed/21041595", "https://www.ncbi.nlm.nih.gov/pubmed/21041595", "https://www.ncbi.nlm.nih.gov/pubmed/21041595", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Blyth%20CC%5BAuthor%5D&cauthor=true&cauthor_uid=26646548", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Blyth%20CC%5BAuthor%5D&cauthor=true&cauthor_uid=26646548", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Blyth%20CC%5BAuthor%5D&cauthor=true&cauthor_uid=26646548", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Jacoby%20P%5BAuthor%5D&cauthor=true&cauthor_uid=26646548", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Jacoby%20P%5BAuthor%5D&cauthor=true&cauthor_uid=26646548", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Jacoby%20P%5BAuthor%5D&cauthor=true&cauthor_uid=26646548", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Effler%20PV%5BAuthor%5D&cauthor=true&cauthor_uid=26646548", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Effler%20PV%5BAuthor%5D&cauthor=true&cauthor_uid=26646548", "https://www.ncbi.nlm.nih.gov/pubmed/26646548", "https://www.ncbi.nlm.nih.gov/pubmed/26646548", "https://www.ncbi.nlm.nih.gov/pubmed/26646548", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Esposito%20S%5BAuthor%5D&cauthor=true&cauthor_uid=21464195", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Esposito%20S%5BAuthor%5D&cauthor=true&cauthor_uid=21464195", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Esposito%20S%5BAuthor%5D&cauthor=true&cauthor_uid=21464195", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Pugni%20L%5BAuthor%5D&cauthor=true&cauthor_uid=21464195", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Pugni%20L%5BAuthor%5D&cauthor=true&cauthor_uid=21464195", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Pugni%20L%5BAuthor%5D&cauthor=true&cauthor_uid=21464195", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Daleno%20C%5BAuthor%5D&cauthor=true&cauthor_uid=21464195", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Daleno%20C%5BAuthor%5D&cauthor=true&cauthor_uid=21464195", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Esposito+S%2C+Pugni+L%2C+Daleno+C%2C+Ronchi+A%2C+Valzano+A%2C+Serra+D%2C+et+al.+InfluenzaA%2FH1N1+MF59-adjuvanted+vaccine+in+preterm+and+term+children+aged+6+to+23months.+Pediatrics+2011%3B127(5)%3Ae1161%E2%80%938.", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Esposito+S%2C+Pugni+L%2C+Daleno+C%2C+Ronchi+A%2C+Valzano+A%2C+Serra+D%2C+et+al.+InfluenzaA%2FH1N1+MF59-adjuvanted+vaccine+in+preterm+and+term+children+aged+6+to+23months.+Pediatrics+2011%3B127(5)%3Ae1161%E2%80%938.", "https://www.hse.ie/eng/health/immunisation/pubinfo/flu-vaccination/", "https://www.hse.ie/eng/health/immunisation/pubinfo/flu-vaccination/", "https://www.hse.ie/eng/health/immunisation/pubinfo/flu-vaccination/", "https://www.hse.ie/eng/health/immunisation/pubinfo/flu-vaccination/", "http://apps.who.int/immunization_monitoring/globalsummary/schedules", "http://apps.who.int/immunization_monitoring/globalsummary/schedules", "https://www.health.govt.nz/publication/immunisation-handbook-2017", "https://www.health.govt.nz/publication/immunisation-handbook-2017", "https://www.health.govt.nz/publication/immunisation-handbook-2017", "https://www.health.govt.nz/publication/immunisation-handbook-2017", "https://www.health.govt.nz/publication/immunisation-handbook-2017", "https://www.health.govt.nz/publication/immunisation-handbook-2017", "https://www.health.gov.il/English/Topics/Pregnancy/Vaccination_of_infants/Pages/vaccine_premature_baby.aspx", "https://www.health.gov.il/English/Topics/Pregnancy/Vaccination_of_infants/Pages/vaccine_premature_baby.aspx", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Walter%20EB%5BAuthor%5D&cauthor=true&cauthor_uid=19935270", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Walter%20EB%5BAuthor%5D&cauthor=true&cauthor_uid=19935270", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Walter%20EB%5BAuthor%5D&cauthor=true&cauthor_uid=19935270", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Englund%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=19935270", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Englund%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=19935270", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Englund%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=19935270", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Blatter%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19935270", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Blatter%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19935270", "https://www.ncbi.nlm.nih.gov/pubmed/?term=PIDJ+2009%3B28%3A1099-1104", "https://www.ncbi.nlm.nih.gov/pubmed/?term=PIDJ+2009%3B28%3A1099-1104", "https://www.ncbi.nlm.nih.gov/pubmed/?term=PIDJ+2009%3B28%3A1099-1104", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Englund%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=19934787", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Englund%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=19934787", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Englund%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=19934787", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Walter%20E%5BAuthor%5D&cauthor=true&cauthor_uid=19934787", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Walter%20E%5BAuthor%5D&cauthor=true&cauthor_uid=19934787", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Walter%20E%5BAuthor%5D&cauthor=true&cauthor_uid=19934787", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Black%20S%5BAuthor%5D&cauthor=true&cauthor_uid=19934787", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Black%20S%5BAuthor%5D&cauthor=true&cauthor_uid=19934787", "https://www.ncbi.nlm.nih.gov/pubmed/19934787", "https://www.ncbi.nlm.nih.gov/pubmed/19934787", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Halasa%20NB%5BAuthor%5D&cauthor=true&cauthor_uid=18444800", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Halasa%20NB%5BAuthor%5D&cauthor=true&cauthor_uid=18444800", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Halasa%20NB%5BAuthor%5D&cauthor=true&cauthor_uid=18444800", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Gerber%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=18444800", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Gerber%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=18444800", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Gerber%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=18444800", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Chen%20Q%5BAuthor%5D&cauthor=true&cauthor_uid=18444800", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Chen%20Q%5BAuthor%5D&cauthor=true&cauthor_uid=18444800", "https://www.ncbi.nlm.nih.gov/pubmed/18444800", "https://www.ncbi.nlm.nih.gov/pubmed/18444800", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Moro%20PL%5BAuthor%5D&cauthor=true&cauthor_uid=20965490", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Moro%20PL%5BAuthor%5D&cauthor=true&cauthor_uid=20965490", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Moro%20PL%5BAuthor%5D&cauthor=true&cauthor_uid=20965490", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Broder%20K%5BAuthor%5D&cauthor=true&cauthor_uid=20965490", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Broder%20K%5BAuthor%5D&cauthor=true&cauthor_uid=20965490", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Broder%20K%5BAuthor%5D&cauthor=true&cauthor_uid=20965490", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Broder%20K%5BAuthor%5D&cauthor=true&cauthor_uid=20965490", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Broder%20K%5BAuthor%5D&cauthor=true&cauthor_uid=20965490", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Broder%20K%5BAuthor%5D&cauthor=true&cauthor_uid=20965490", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Zheteyeva%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=20965490", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Zheteyeva%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=20965490", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Zheteyeva%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=20965490", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Zheteyeva%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=20965490", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Zheteyeva%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=20965490", "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685674/", "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685674/", "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685674/", "https://www.ncbi.nlm.nih.gov/pubmed/?term=M%C3%B8lgaard-Nielsen%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31259452", "https://www.ncbi.nlm.nih.gov/pubmed/?term=M%C3%B8lgaard-Nielsen%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31259452", "https://www.ncbi.nlm.nih.gov/pubmed/?term=M%C3%B8lgaard-Nielsen%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31259452", "https://www.ncbi.nlm.nih.gov/pubmed/?term=M%C3%B8lgaard-Nielsen%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31259452", "https://www.ncbi.nlm.nih.gov/pubmed/?term=M%C3%B8lgaard-Nielsen%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31259452", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Fischer%20TK%5BAuthor%5D&cauthor=true&cauthor_uid=31259452", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Fischer%20TK%5BAuthor%5D&cauthor=true&cauthor_uid=31259452", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Fischer%20TK%5BAuthor%5D&cauthor=true&cauthor_uid=31259452", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Krause%20TG%5BAuthor%5D&cauthor=true&cauthor_uid=31259452", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Krause%20TG%5BAuthor%5D&cauthor=true&cauthor_uid=31259452", "https://www.ncbi.nlm.nih.gov/pubmed/31259452", "https://www.ncbi.nlm.nih.gov/pubmed/31259452", "https://www.ncbi.nlm.nih.gov/pubmed/31259452", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20J%5BAuthor%5D&cauthor=true&cauthor_uid=16784533", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20J%5BAuthor%5D&cauthor=true&cauthor_uid=16784533", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20J%5BAuthor%5D&cauthor=true&cauthor_uid=16784533", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Robinson%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=16784533", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Robinson%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=16784533", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Robinson%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=16784533", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Spady%20DW%5BAuthor%5D&cauthor=true&cauthor_uid=16784533", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Spady%20DW%5BAuthor%5D&cauthor=true&cauthor_uid=16784533", "https://www.ncbi.nlm.nih.gov/pubmed/16784533", "https://www.ncbi.nlm.nih.gov/pubmed/16784533", "https://www.ncbi.nlm.nih.gov/pubmed/16784533", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Carbone%20T%5BAuthor%5D&cauthor=true&cauthor_uid=18450851", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Carbone%20T%5BAuthor%5D&cauthor=true&cauthor_uid=18450851", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Carbone%20T%5BAuthor%5D&cauthor=true&cauthor_uid=18450851", "https://www.ncbi.nlm.nih.gov/pubmed/?term=McEntire%20B%5BAuthor%5D&cauthor=true&cauthor_uid=18450851", "https://www.ncbi.nlm.nih.gov/pubmed/?term=McEntire%20B%5BAuthor%5D&cauthor=true&cauthor_uid=18450851", "https://www.ncbi.nlm.nih.gov/pubmed/?term=McEntire%20B%5BAuthor%5D&cauthor=true&cauthor_uid=18450851", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Kissin%20D%5BAuthor%5D&cauthor=true&cauthor_uid=18450851", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Kissin%20D%5BAuthor%5D&cauthor=true&cauthor_uid=18450851", "https://www.ncbi.nlm.nih.gov/pubmed/18450851", "https://www.ncbi.nlm.nih.gov/pubmed/18450851", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Klein%20NP%5BAuthor%5D&cauthor=true&cauthor_uid=18310193", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Klein%20NP%5BAuthor%5D&cauthor=true&cauthor_uid=18310193", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Klein%20NP%5BAuthor%5D&cauthor=true&cauthor_uid=18310193", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Massolo%20ML%5BAuthor%5D&cauthor=true&cauthor_uid=18310193", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Massolo%20ML%5BAuthor%5D&cauthor=true&cauthor_uid=18310193", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Massolo%20ML%5BAuthor%5D&cauthor=true&cauthor_uid=18310193", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Greene%20J%5BAuthor%5D&cauthor=true&cauthor_uid=18310193", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Greene%20J%5BAuthor%5D&cauthor=true&cauthor_uid=18310193", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Greene+J%2C+Dekker+CL%2C+Black+S%2C+Escobar+GJ", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Greene+J%2C+Dekker+CL%2C+Black+S%2C+Escobar+GJ", "https://twitter.com/diariofarma", "https://www.addtoany.com/add_to/facebook?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/twitter?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/whatsapp?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/linkedin?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/meneame?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/email?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/printfriendly?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/add_to/flipboard?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros", "https://www.addtoany.com/share", "https://www.diariofarma.com?&utm_source=portadabajo_noticia", "https://diariofarma.com/2019/11/28/los-prematuros-ya-tienen-calendario-vacunal-oficial-con-rotavirus-y-gripe", "https://diariofarma.com/2019/11/28/los-prematuros-ya-tienen-calendario-vacunal-oficial-con-rotavirus-y-gripe", "https://diariofarma.com/2019/07/09/coberturas-vacunales-2018-rompe-la-senda-alcista-previa-y-retrocede", "https://diariofarma.com/2019/07/09/coberturas-vacunales-2018-rompe-la-senda-alcista-previa-y-retrocede", "https://diariofarma.com/2018/10/22/que-vacunas-son-recomendables-mas-alla-del-calendario-vacunal", "https://diariofarma.com/2018/10/22/que-vacunas-son-recomendables-mas-alla-del-calendario-vacunal", "https://diariofarma.com/2022/02/02/el-cav-aep-destaca-el-exito-de-las-coberturas-en-la-primovacunacion-a-pesar-de-las-dificultades-de-la-covid-19", "https://diariofarma.com/2022/02/02/el-cav-aep-destaca-el-exito-de-las-coberturas-en-la-primovacunacion-a-pesar-de-las-dificultades-de-la-covid-19", "https://diariofarma.com/2021/10/01/espana-se-acerca-a-la-normalidad", "https://diariofarma.com/2021/10/01/espana-se-acerca-a-la-normalidad", "https://diariofarma.com/2021/06/05/el-boe-publica-la-polemica-declaracion-de-actuaciones-coordinadas-de-darias", "https://diariofarma.com/2021/06/05/el-boe-publica-la-polemica-declaracion-de-actuaciones-coordinadas-de-darias", "https://diariofarma.com/2019/06/13/la-aep-analiza-las-diferencias-entre-ccaa-en-el-calendario-unico-de-2019", "https://diariofarma.com/2019/06/13/la-aep-analiza-las-diferencias-entre-ccaa-en-el-calendario-unico-de-2019", "https://diariofarma.com/2019/05/22/el-calendario-unico-de-vacunacion-y-el-gato-de-schroedinger", "https://diariofarma.com/2019/05/22/el-calendario-unico-de-vacunacion-y-el-gato-de-schroedinger", "https://diariofarma.com/2018/10/08/sanidad-publica-un-informe-sobre-vacunacion-en-grupos-de-riesgo", "https://diariofarma.com/2018/10/08/sanidad-publica-un-informe-sobre-vacunacion-en-grupos-de-riesgo", "https://diariofarma.com/2022/11/11/expertos-en-vacunas-ven-un-futuro-esperanzador-ante-la-enfermedad-neumococica", "https://diariofarma.com/2022/11/11/expertos-en-vacunas-ven-un-futuro-esperanzador-ante-la-enfermedad-neumococica", "https://diariofarma.com/2022/10/06/mas-ccaa-dan-el-paso-de-mejorar-su-calendario-vacunal-respecto-al-comun", "https://diariofarma.com/2022/10/06/mas-ccaa-dan-el-paso-de-mejorar-su-calendario-vacunal-respecto-al-comun", "https://diariofarma.com/2022/09/26/espana-se-abona-al-cuatro-pinchazo", "https://diariofarma.com/2022/09/26/espana-se-abona-al-cuatro-pinchazo", "https://www.kernpharmacias.com/s/", "http://www.msd.es/?utm_source=diariofarma&utm_medium=display&utm_campaign=comunicaci%C3%B3n_2018&utm_content=banner_300x250", "https://www.diariofarma.com/newsletter?utm_source=banner_lateral_nwlett", "https://www.diariofarma.com/linkout/27673", "https://www.kernpharma.com/es/actividad/finisher", "https://www.diariofarma.com/2020/10/19/las-agencias-van-a-evaluar-las-vacunas-con-el-rigor-de-siempre-haciendo-oidos-sordos-a-la-urgencia?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2020/10/18/soy-vehemente-ante-alguien-que-me-dice-que-la-farmacia-no-es-clinica?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2020/02/18/no-apoyamos-el-multiswitch-es-malo-para-el-paciente-y-para-el-sns?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2019/11/24/llevo-20-anos-escuchando-que-el-sns-no-es-sostenible-pero-somos-el-sistema-mas-eficiente-de-toda-europa?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2020/01/28/vamos-a-tener-avances-extraordinarios-y-las-decisiones-las-tendremos-que-tomar-entre-todos?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2019/12/02/con-vision-ambiciosa-y-de-reforma-profunda-cubriremos-temas-amplios?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2019/11/16/entrevista-con-patricia-lacruz-sobre-el-plan-de-genericos-y-biosimilares?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2019/10/19/vamos-a-seguir-edificando-sobre-lo-que-ya-nos-hemos-encontrado-que-es-muchisimo?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df\"", "https://www.diariofarma.com/2019/04/07/en-la-segunda-parte-del-partido-tenemos-que-consolidar-lo-realizado?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2019/03/31/las-decisiones-del-cisns-deben-ser-vinculantes-la-cohesion-y-la-equidad-interterritorial-son-basicas?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2019/04/15/algunos-acuerdos-del-consejo-interterritorial-deben-ser-vinculantes?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2019/02/05/no-vamos-a-entrar-en-debates-con-los-proveedores-la-evidencia-nos-guiara?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2019/10/08/somos-punteros-en-tecnologia-nadie-en-el-mundo-esta-tan-avanzado?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2018/07/10/con-la-nueva-estrategia-de-cronicos-reordenamos-nuestros-recursos?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2019/01/15/debemos-unirnos-para-que-la-venta-por-internet-se-haga-colectivamente?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2018/10/24/la-atencion-domiciliaria-y-el-sft-lo-hacen-enfermeria-y-ap-y-debe-ser-asi?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2019/04/24/creemos-en-la-necesidad-de-ir-a-un-sistema-nuevo-de-pago-por-valor?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2018/11/15/el-farmaceutico-tiene-que-intervenir-antes-de-que-el-paciente-lo-necesite?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2018/01/14/valoraremos-una-accion-estrategica-abordar-la-factura-farmaceutica?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2017/11/25/siempre-pedimos-interterritorial-vinculante-tenemos-la-herramienta?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2017/11/22/potenciar-la-af-farmaceutico-no-solo-dispense-fundamental?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2017/09/20/importante-la-farmacia-crezca-queremos-preservar-modelo?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/2017/07/07/las-fusiones-pueden-racionalizar-la-actividad-las-distribuidoras?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "https://www.diariofarma.com/category/entrevista?&utm_source=descatadas&utm_medium=webdf&utm_campaign=destac_df", "\r\n/quienes-somos", "\r\nhttps://www.diariofarma.com/politica-de-cookies", "\r\nhttps://www.diariofarma.com/politica-de-privacidad", "\r\nhttps://www.diariofarma.com/aviso-legal", "\r\nhttps://sp.depositphotos.com/stock-photography.html", "\r\nmailto:df@diariofarma.com", "#", "https://www.addtoany.com/add_to/facebook?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros%20%7C%20%40diariofarma", "https://www.addtoany.com/add_to/twitter?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros%20%7C%20%40diariofarma", "https://www.addtoany.com/add_to/whatsapp?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros%20%7C%20%40diariofarma", "https://www.addtoany.com/add_to/linkedin?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros%20%7C%20%40diariofarma", "https://www.addtoany.com/add_to/meneame?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros%20%7C%20%40diariofarma", "https://www.addtoany.com/add_to/email?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros%20%7C%20%40diariofarma", "https://www.addtoany.com/add_to/printfriendly?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros%20%7C%20%40diariofarma", "https://www.addtoany.com/add_to/flipboard?linkurl=https%3A%2F%2Fdiariofarma.com%2F2019%2F11%2F28%2Fvacunacion-en-prematuros&linkname=Calendario%20de%20vacunaci%C3%B3n%20en%20reci%C3%A9n%20nacidos%20prematuros%20%7C%20%40diariofarma", "https://www.addtoany.com/share", "https://www.diariofarma.com/politica-de-cookies", "http://wordpress.org/plugins/asesor-cookies-para-la-ley-en-espana/", "javascript:;", null, "#"]}